Protocol Amendment 2 J2G-OX-JZJT (LOXO-RET-[ZIP_CODE]) 
A Phase 1, Open-label, Two-part Study to Investigate the Absorption, Metabolism and Excretion and the 
Absolute Bioavailbility of [ l 4C]-LOXO-292 in Healthy Male Subjects 
[STUDY_ID_REMOVED] 
Approval Date: 15-Aug-[ADDRESS_663873] 2 0 1 8 Pa ge 1 of 6 0 A P H A S E 1, O P E N- L A B E L, T W O- P A R T S T U D Y T O I N V E S TI G A T E T H E 
A B S O R P TI O N, M E T A B O LI S M, A N D E X C R E TI O N, A N D T H E A B S O L U T E 
BI O A V AI L A BI LI T Y O F [1 4C]- L O X O- 2 9 2 I N H E A L T H Y M A L E S U B J E C T S 
Pr ot oc ol A me n d me nt 2 Stat us:  Fi nal  
Pr ot oc ol A me n d me nt 2 Date:  [ADDRESS_663874] 2 0 1 8 
Pr ot oc ol A me n d me nt 1 Date:  1 2 J ul y 2 0 1 8 
Ori gi nal Pr ot oc ol D ate:  [ADDRESS_663875] u g: L O X O- 2 9 2 
S p o ns or Refere n ce N u m ber: L O X O- R E T- [ADDRESS_663876] u d y N u m ber: 8 3 8 7 0 2 4 
I N D N u m ber: [ADDRESS_663877] 2 0 1 8 Pa ge 2 of 6 0 S T U D Y I D E N TI FI C A TI O N 
S p o ns or L o x o  O nc ol o g y, I nc.
7 0 1  Gate wa y  B o ule v ar d, S uite 4 2 0
S o ut h Sa n Fra ncisc o, Calif or nia 9 4 0 8 0 
( 6 5 0) 9 8 9- 8 0 5 1 ( M ai n Tele p h o ne N o.)
S p o ns or’s St u d y C o ntact  
L o x o  O nc ol o g y, I nc.
 ( M o bile Tele p h o ne N o.) 
 ( Alter nat e C o ntact N o.) 
S p o ns or’s Me dical M o nit or  
C o ns ulti n g t o L o x o O nc ol o g y, I nc. 
 ( M o bile Tele p h o ne N o.) 
S p o ns or C o ntact I nf or mati o n f or Seri o us A d verse  Safet y fa x:  + 1 ( 2 0 3) 6 4 3- 2 0 1 3 
E ve nt Re p orti n g Safet y e mail:  safet y @l o x o o nc ol o g y. c o m  
Cli nical Site C o va nce Cli nical Researc h U nit, I nc. 
3 4 0 2 Ki ns ma n B o ule var d 
Ma dis o n, Wisc o nsi n 5 3 7 0 4 ( 6 0 8) 4 4 2- 8 2 0 0 ( M ai n Tele p h o ne N o.)( 6 0 8) 6 6 1- 8 1 6 9 ( M ai n Facsi mile N o.)
Pri nci pal I n v esti gat or P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
Pr ot oc ol A me n d me nt [ADDRESS_663878] 
Ma dis o n, Wisc o nsi n 5 3 7 1 5 ( 6 0 8) 4 1 7- 6 5 2 9 ( M ai n Tele p h o ne N o.)
Bi oa nal ytical La b orat or y  Alt uras A nal ytics, I nc. 
1 3 2 4 Alt uras Dri ve  M osc o w, I da h o 8 3 8 4 3 ( 2 0 8) 8 8 3- 3 4 0 0 ( M ai n Tele p h o ne N o.)
Ra di oa nal ytical La b orat or y  C o va nce La b orat ories, I n c. ( Part 1) De part me nt of Dr u g Me t a b olis m a n d P har mac o ki netics 
3 3 0 1 Ki ns ma n B o ule var d Ma dis o n, Wisc o nsi n 5 3 7 0 4 ( 6 0 8) 2 4 1- 4 4 7 1 ( M ai n Tele p h o ne N o.)
Meta b olite Pr ofili n g La b  C o va nce La b orat ories, I n c. ( Part 1) De part me nt of Dr u g Met a b olis m a n d P har mac o ki netics 3 3 0 1 Ki ns ma n B o ule var d Ma dis o n, Wisc o nsi n 5 3 7 0 4 
( 6 0 8) 2 4 1- 4 4 7 1 ( M ai n Tele p h o ne N o.)
Ra di oa nal ytical La b orat or y  P har mar o n (f or merl y X celer o n) 
( Part 2) 2 0 3 4 0 Se neca M ea d o ws Par k wa y 
Ger ma nt o w n,  Mar yla n d 2 0 8 7 6
( 2 4 0) 3 6 1- 1 9 0 0 ( M ai n Tele p h o ne N o.)
P har mar o n St u d y C o ntact P P D
P P D
P P D
Pr ot oc ol A me n d me nt [ADDRESS_663879] u d y R estricti o ns ...................................................................................... 3 8  
6. 3. 1 Diet, Fl ui d, a n d Acti vit y C o ntr ol ................................................... 3 8  
6. 3. 2 C o nc o mita nt Me dicati o ns .............................................................. 3 9  
6. 3. 3 C o ntrace pti o n  ................................................................................. 3 9  
6. 4 P har mac o ki netic, [1 4C] Ra di oacti vit y, a n d Meta b olite Pr oce d ures ........... 4 0  
6. 4. 1 P har mac o ki netic, [1 4C] Ra di oacti vit y, a n d Meta b olite Bl o o d Sa m ple 
C ollecti o n  ........................................................................... 4 0  
6. 4. 2 P har mac o ki netic, [1 4C] Ra di oacti vit y, a n d Meta b olite Uri ne Sa m ple 
C ollecti o n  ........................................................................... 4 0  
6. 4. 3 [1 4C] Ra di oacti vit y a n d Meta b olite Fecal Sa m ple C ollecti o n........ [ADDRESS_663880] 2 0 1 8 Pa ge 7 of 6 0 8. 2 Site I nitiati o n Visit/I n vesti gat or Meeti n g .................................................. 4 9  
8. 3 Discl os ure .................................................................................................. 4 9  
8. 4 M o nit ori n g ................................................................................................. 4 9  
8. 5 I nstit uti o nal Re vie w B oar d ........................................................................ 5 0  
8. 6 I nf or me d C o nse nt....................................................................................... 5 0  
8. 7 Rec or ds ...................................................................................................... 5 0  
8. 8 Refere n ce t o D eclarati o n of Helsi n ki/ Basic Pri nci ples .............................. [ADDRESS_663881] 2 0 1 8 Pa ge 8 of 6 0 T A B L E O F T A B L E S A N D FI G U R E S 
Ta ble 6- 1  Sc he d ul e of Assess me nts:  Part 1 .................................................................... 3 0  
Ta ble 6- 2  Sc he d ul e of Assess me nts:  Part [ADDRESS_663882] u gs:  Part [ADDRESS_663883] u gs:  Part [ADDRESS_663884] u d y Desi g n Sc he matic:  Part [ADDRESS_663885] u d y Desi g n Sc he matic:  Part [ADDRESS_663886] 2 0 1 8 Pa ge 9 of 6 0 A B B R E VI A TI O N S 
A D L  Acti vities of Dail y Li vi n g 
Aef  a m o u nt e x crete d i n feces per sa m pli n g i nter val 
Ae u  a m o u nt e x crete d i n uri ne per sa m pli n g i nter val 
A E a d verse  e ve nt
A L A R A   as l o w as (is) reas o na bl y ac hie va bl e A L P al kali ne  p h os p hataseA L T ala ni ne  a mi n otra nsf eras eA M E   a bs or pti o n, meta b olis m, a n d e x creti o n A M S   accelerat or mass s pectr o metr y 
A S T as partate  a mi n otra nsferas e
A U C   area u n d er t he c o nce ntrati o n-ti me c ur ve A U C
0- ∞  area u n d er t he c o nce ntrati o n-ti me c ur ve e xtra p olat e d t o i nfi nit y 
A U C last  area u n d er t he c o nce ntrati o n-ti me c ur ve fr o m ti me [ADDRESS_663887] q ua ntifia ble c o nce ntr ati o n 
C L/ F a p pare nt  s yste mic  cleara nce
C LR re nal  cleara nce
Cma x  ma xi m u m o bser ve d c o nce ntrati o n 
C R U   Cli nical Researc h U nit C T C A E   C o m m o n Ter mi n ol o g y Criteria f or A d vers e E ve nts C u m A
ef  c u m ulati ve a m o u nt e x crete d i n feces 
C u m A e u  c u m ulati ve a m o u nt e x crete d i n uri ne 
C u m % f ef  c u m ulati ve perce nta ge of d ose e x crete d i n feces 
C u m % f e u   c u m ulati ve perce nta ge of d ose e x crete d i n uri ne   
C Y P c yt o c hr o me  P [ADDRESS_663888] u g A d mi nistrati o n 
%fef  perce nt a ge of d os e e x cret e d i n feces per s a m pli n g i nter val 
%fe u  perce nt a ge of d os e e x cret e d i n uri ne per s a m pli n g i nter val 
GI gastr oi ntesti nal
G L P G o o d  La b orat or y  PracticeH Bc A b  he patitis B c ore a nti b o d y H Bs A g   he patitis B s urface a nti ge n H C V A b   he patitis C vir us a nti b o d y h E R G   h u ma n et her- a- g o- g o relate d ge ne HI V h u ma n  i m m u n o deficie nc y  vir usI B I n v esti gat or’s Br oc h ure 
I C F I nf or me d  C o nse nt  F or mI R B I nstit uti o nal  Re vie w  B oar dI U D i ntra uteri ne  de vic eI V i ntra ve n o us(l y)
Z  a p pare nt ter mi nal eli mi nati o n rate c o nsta nt 
L F T   li ver f u ncti o n test L S C   li q ui d sci ntillati o n c o u nti n g P K p har mac o ki netic(s)R B C   re d bl o o d cell R E T   rearra n ge d d uri n g tra nsf ecti o n 
Q Tc   Q T i nter val c orrecte d f or heart rate  
Q Tc F  Q T i nter val c orrecte d f or heart rate usi n g Fri d erici a’s met h o d S A E   seri o us a d vers e e v e nt S A P   Statistical A nal ysis Pla n t
1/ [ADDRESS_663889] ate 
Vz  v ol u me of distri b uti o n d uri n g t he ter mi nal p hase 
Vz/ F  a p pare nt v ol u me of distri b uti o n d uri n g t he ter mi nal p hase 
W B C  w hite bl o o d cell 
Pr ot oc ol A me n d me nt [ADDRESS_663890] u d y: A P hase 1, O pe n-la bel, T w o- p art St u d y t o I n vesti gate t he A bs or pti o n, Meta b olis m, a n d 
E xcreti o n, a n d t he A bs ol ute Bi oa vaila bilit y of [1 4C]- L O X O- 2 9 2 i n Healt h y Male 
S u bj ects  
O bj ecti ves: P art 1: Pri mar y:  
 T o deter mi ne mass bala nce a n d r o utes of eli mi nati o n of [
1 4C]- L O X O- 2 9 2 f oll o wi n g 
oral a d mi nistrati o n of a si n gle 1 6 0- m g ( ~ 4 0 μ Ci) ra di ola bele d d ose of L O X O- 2 9 2 i n healt h y male s u bj ects 
 T o assess t he p har mac o ki netics ( P K) of a si n gle oral d ose of L O X O- 2 9 2 usi n g 
[
1 4C]- L O X O- 2 9 2 
 T o deter mi ne t he w h ole bl o o d a n d plas ma  c o nce ntrati o ns of t otal ra di oacti vit y 
 T o deter mi ne t he uri nar y a n d fecal rec o ver y of t otal ra di oacti vit y 
 T o c haracterize a n d i de n tif y meta b olites of [1 4C]- L O X O- 2 9 2 i n plas ma, uri ne, a n d 
feces. 
Sec o n dar y:  
 T o assess t he safet y a n d t olera bilit y of [1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 4 0 μ Ci). 
P art 2:  
Pri mar y:  
 T o deter mi ne t he a bs ol ute bi oa vaila bilit y of L O X O- 2 9 2 f oll o wi n g a si n gle oral d ose 
of 1 6 0 m g of L O X O- 2 9 2 al o n g wit h a n i ntra ve n o us (I V) d ose of < 1 0 0 μ g of [
1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci) 
 T o e val uate t he P K of L O X O- 2 9 2  f oll o wi n g oral a n d I V d osi n g  
 T o e val uate t he uri nar y e xcreti o n of L O X O- 2 9 2 f oll o wi n g oral d osi n g a n d of 
[1 4C]- L O X O- 2 9 2 f oll o wi n g I V d osi n g 
 T o e val uate t he fecal rec o ver y of t otal ra di oacti vit y f oll o wi n g I V d osi n g of 
[1 4C]- L O X O- 2 9 2. 
Sec o n dar y:  
 T o assess t he safet y a n d t olera bilit y of L O X O- 2 9 2. 
Met h o d ol o g y/ St u d y Desi g n:  T his st u d y will be a n o pe n-la bel, 2- part a bs or pti o n, meta b olis m,  e xcreti o n ( A M E) a n d a bs ol ute bi oa vaila bilit y st u d y of [
1 4C]- L O X O- 2 9 2 . S u bj ects i n P art 1 will n ot p artici pate 
i n P art 2, n or will s u bj ects i n P art 2 partici pate i n P art 1. P art 1 a n d P art 2 are 
i n de p e n de nt of eac h ot her a n d d o n ot nee d t o be c o n d ucte d i n se q ue ntial or der.  
P art 1 is desi g ne d t o e val uate t he A M E ki netics of L O X O- 2 9 2, t o i de ntif y a n d 
c haracterize meta b olites of L O X O - 2 9 2, a n d t o assess t he safet y a n d t olera bilit y of 
[1 4C]- L O X O- 2 9 2. S u bj ects i n P art 1 will be a d mi nistere d a si n gle oral d ose of 1 6 0 m g of 
[1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 4 0 μ Ci) as a n oral s ol uti o n. I n or der t o c o m plete 
6  s u bj ects, 6 will be e nr olle d ( differe nt s ubj ects fr o m t h ose partici pati n g i n P art 2) , al o n g wit h 2  alter nates (t o be d ose d i n t he e ve nt t hat d osi n g is u ns uccessf ul f or a n y of t he i nitial 6 s u bj ects). I n t he e ve nt of earl y wit h dra wal of a n y s u bj ects after t he alter nate 
s u bj ects are release d, re place me nt s u bj ects ma y be e nr olle d at t he discreti o n of t he 
S p o ns or.    
P art 2 is desi g ne d t o deter mi ne t he a bs ol ute bi oa vaila bilit y  of L O X O- 2 9 2, t o e val uate t he 
uri n ar y e xcreti o n of L O X O- 2 9 2 a n d [
1 4C]- L O X O- 2 9 2, t o e val uate t he fecal e xcreti o n of 
[1 4C]- L O X O- 2 9 2, a n d t o assess t he safet y a n d t olera bilit y of L O X O- 2 9 2. S u bj ects i n 
P art  2 will be a d mi nistere d a si n gle oral d ose of 1 6 0 m g of L O X O- 2 9 2 as 2 x 8 0- m g 
ca ps ule s f oll o we d 2 h o urs later b y a si n gle d ose of < 1 0 0 μ g of [1 4C]- L O X O- 2 9 2 
(c o ntai ni n g ~ 1 μ Ci) a d mi nistere d as a n I V p us h o ver a p pr o xi matel y 2 mi n utes. I n or der 
t o c o m plete 6 s u bj ects, 6 will be e nr olle d ( differe nt s u bj ects fr o m t h ose partici pati n g i n 
P art 1), al o n g wit h 2 alter nates (t o be d ose d i n t he e ve nt t hat d osi n g is u ns uccessf ul f or 
Pr ot oc ol A me n d me nt [ADDRESS_663891] 2 0 1 8 Pa ge 1 2 of 6 0 a n y of t he i nitial 6 s u bj ects). I n t he e ve nt of earl y wit h dra wal of a n y s u bj ects after t he 
alter nate s u bj ects are release d, re place me nt s u bj ects ma y be e nr olle d at t he discreti o n of t he S p o ns or.   
T he star t of t he st u d y is defi ne d as t he earliest d ate a s u bj ect w h o is e nr olle d i n eit her part 
of t he st u d y  si g ns a n I nf or me d C o nse nt F or m. A s u bj ect w h o c o m pletes s ufficie nt 
L O X O - 2 9 2, [
1 4C]- L O X O- 2 9 2 ( P art 2 o nl y), t otal ra di oacti vit y, a n d meta b olite ( P art 1 
o nl y)  sa m pli n g pri or t o Cli nic Disc har ge is c o nsi dere d t o ha v e c o m plete d t he st u d y. T he 
e n d of t he st u d y is defi ne d as t he latest date a s u bj ect recei ves t he Safet y F oll o w- u p Call. T he pla n ne d d urati o n of st u d y c o n d uct f or P art  [ADDRESS_663892] f or P art 2 is u p t o 4 6 da ys fr o m Scree ni n g t hr o u g h t he Safet y F oll o w- u p Call. 
P art 1:  
After a Scree ni n g peri o d of u p t o 2 8  da ys, s u bj ects will c hec k i n t o t he Cli nical Researc h 
U nit ( C R U) o n Da y - [ADDRESS_663893] 8  h o urs, 
s u bj ects will recei ve a si n gle oral d ose of 16 0 m g of [
1 4C]- L O X O- 2 9 2 
(c o ntai ni n g ~ 4 0 μ Ci) a d mi nist ere d as a n oral s ol uti o n. S u bj ects will be c o nfi ne d at t he 
C R U fr o m t he ti me of C hec k -i n u ntil Cli nic Disc har ge ( bet wee n Da ys 8 a n d 2 2). After c o m pleti n g disc har ge pr oce d ures, s u bj ects will be disc har ge d fr o m t he C R U as earl y as Da y 8 a n d u p t o Da y 2 2 , pr o vi de d rec o ver y of ra di oacti vit y has reac he d t he f oll o wi n g 
t hres h ol d val ues: 
 ≥  9 0 % of t he ra di oacti ve d ose is rec o vere d, a n d  
 ≤  1 % of t he ra di oacti ve d ose per da y is rec o vere d i n e xcreta ( uri ne a n d feces) 
f or [ADDRESS_663894] u d y, safet y will be m o nit ore d wit h a d verse e ve nt ( A E) i n q uiries, cli nical 
la b orat or y e val uati o ns, vital si g ns meas ure me nts, 1 2-lea d ele ctr ocar di o gra ms ( E C Gs), a n d p h ysical e xa mi nati o n s d uri n g t he st u d y.  
Sa m ples f or deter mi nati o n of L O X O -2 9 2 c o nce ntrati o ns i n plas ma, t otal ra di oacti vit y 
c o nce ntrati o ns i n plas ma, w h ole bl o o d, uri ne, a n d feces, a n d f or meta b olite 
pr ofili n g/c haracterizati o n will be o btai ne d t hr o u g h at least [ADDRESS_663895] d ose ( Da y  8), 
a n d p os si bl y u p t o [ADDRESS_663896] d ose ( Da y 2 2). 
P art 2:  
After a Scree ni n g peri o d of u p t o [ADDRESS_663897] 8 h o urs, s u bj ects will recei ve a si n gle oral 
d ose of 1 6 0 m g of L O X O- 2 9 2 as 2 x 8 0- m g ca ps ules f oll o we d 2 h o urs later b y a si n gle 
d ose of < 1 0 0 μ g of [
1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci) a d mi nistere d as a n I V p us h 
o ver a p pr o xi matel y [ADDRESS_663898] u d y.  
Sa m ples f or deter mi nati o n of plas ma a n d uri ne c o nce ntrati o ns of L O X O - 2 9 2 a n d 
[
1 4C]- L O X O- [ADDRESS_663899] d ose ( Da y 9). 
Pr ot oc ol A me n d me nt [ADDRESS_663900] 2 0 1 8 Pa ge 1 3 of 6 0 N u m ber of S u bj ects: P art 1:  I n or der t o c o m plete 6 s u bj ects, 6 w ill be e nr olle d ( differe nt s u bj ects fr o m t h ose 
partici pati n g i n P art 2) , al o n g wit h 2 alter nates (t o be d ose d i n t he e ve nt t hat d osi n g is 
u ns uccessf ul f or  a n y of t he i nitial 6 s u bj ects). P art 2:  I n or der t o c o m plete 6 s u bj ects, 6 will be e nr olle d ( differe nt s u bj ects fr o m t h ose 
partici pati n g i n P art 1) , al o n g wit h 2 alter nates (t o be d ose d i n t he e ve nt t hat d osi n g is u ns uccessf ul f or a n y of t he i nitial 6  s u bj ects). 
I n P arts [ADDRESS_663901] me nt s u bj ects may be e nr olle d at t he discreti o n of t he S p o ns or. 
Dia g n osis a n d Mai n Criteria f or I ncl usi o n: Healt h y male s u bj ects bet wee n 1 8 a n d 5 5 years of a ge, i ncl usi ve, wit h a b o d y mass i n de x of 1 8. 5 t o 3 2. 0 k g/ m
2, i ncl usi ve. 
T est Pr o d uct(s), D ose, 
a n d M o de of 
A d mi nistrati o n:  P art 1:  S u bj ects will recei ve a si n gle oral d ose of 1 6 0 m g of [1 4C]- L O X O- 2 9 2 
(c o ntai ni n g ~ 4 0 μ Ci) as a n oral s ol uti o n after at least a n 8- h o ur fast. P art 2:   S u bj ects will recei ve a si n gle oral d ose of [ADDRESS_663902] f oll o we d 2 h o urs later b y a si n gle d ose of < 1 0 0 μ g 
of [
1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci) a d mi nistere d as a n I V p us h o ver a p pr o xi matel y 
2 mi n utes.   
D urati o n of Treat me nt: Pla n ne d E nr oll me nt/ Scree ni n g D urati o n:  P art 1; a p pr o xi mat el y 2 8 da ys ( Da ys - 2 9 t o - 2). 
P art 2; a p pr o xi matel y 2 8 da ys ( Da ys - 2 9 t o - 2).   
Le n gt h of C o nfi ne me nt:  Part 1; u p t o 2 3 da ys ( Da ys - 1 t o 2 2). Part 2; 1 0 da ys ( Da ys - 1 t o 9).   Pla n ne d St u d y C o n d uct  D urati o n: P art 1; u p t o 5 9 da ys ( Scre e ni n g t o Safet y F oll o w-u p Call). P art 2; u p t o 4 6 da ys ( S cr ee ni n g t o Safet y F oll o w- u p Call). 
Criteria f or E val uati o n: Safet y Safet y will be m o nit ore d wit h A E i n q uiries, cli nical la b orat or y e val uati o ns, vital si g ns meas ure me nts, E C Gs, a n d p h ysical e xa mi nati o ns. 
Criteria f or E val uati o n: 
P har mac o ki netics  P art 1: W he ne ver p ossi ble, t he f oll o wi n g P K para meters will be calc ulate d base d o n t he plas ma 
c o nce ntrati o ns of L O X O- 2 9 2 a n d o n plas ma a n d w h ole bl o o d c o nce ntrati o ns of t otal 
ra di oacti vit y: ma xi m u m o bser ve d c o nce ntrati o n ( C
ma x), ti me t o ma xi m u m o bser ve d 
c o nce ntrati o n ( T ma x), area u n der t he c o nce ntrati o n-ti me c ur ve ( A U C) fr o m ti me [ADDRESS_663903] q ua ntifia ble c o nce ntrati o n ( A U C l ast), A U C e xtra p olate d t o i nfi nit y 
( A U C 0-), a p pare nt ter mi nal eli mi nati o n rate c o nsta nt ( z), a p pare nt ter mi nal eli mi nati o n 
half -life (t 1/ 2), a p pare nt s yste mic cleara nce ( C L/ F; f or L O X O- 2 9 2 o nl y), a p pare nt v ol u me 
of distri b uti o n  d uri n g t he ter mi nal p hase ( V z/ F; f or L O X O- 2 9 2 o nl y), A U C 0- ∞ of t otal 
ra di oacti vit y i n w h ole bl o o d/ A U C 0- ∞ of t otal ra di oacti vit y i n plas ma ( Bl o o d/ Plas ma A U C 
Rati o) , a n d A U C 0- ∞ of L O X O- 2 9 2 i n plas ma/ A U C 0- ∞ of t otal ra di oacti vit y i n plas ma 
( Plas ma L O X O- 2 9 2/ T otal Ra di oacti vit y A U C Rati o). 
W he ne ver p ossi ble, t he f oll o wi n g P K para meters will be calc ulate d base d o n t he uri ne 
c o nce ntrati o ns of  t otal ra di oacti vit y: a m o u nt e xcrete d i n uri ne per sa m pli n g i nter val 
( Ae u), c u m ulati ve a m o u nt e xcr ete d i n uri ne ( C u m A e u), perce nta ge of d ose e xcrete d i n 
uri ne per sa m pli n g i nte r val ( %f e u), a n d c u m ulati ve perce nta ge of d ose e xcrete d i n uri ne 
( C u m %f e u). 
W he ne ver p ossi ble, t he f oll o wi n g P K para meters will be calc ulate d base d o n t he fecal c o nce ntrati o ns of  t otal ra di oacti vit y: a m o u nt e xcrete d i n feces per sa m pli n g i nter val 
( A
ef), c u m ulati ve a m o u nt e xcr ete d i n feces ( C u m A ef), perce nta ge of d ose e xcrete d i n 
feces per sa m pli n g i nter val ( %f ef), a n d c u m ulati ve perce nta ge of d ose e xcrete d i n feces 
( C u m %f ef). 
P art 2:  F oll o wi n g oral d osi n g of L O X O - 2 9 2, t he f oll o wi n g P K para meters will be calc ulate d, w he ne ver p ossi ble, base d o n t he plas ma c o nce ntrati o ns  of L O X O- 2 9 2:  C
ma x, Tma x, 
A U C last, A U C 0-, z, t1/ 2, a bs ol ute bi oa vaila bilit y ( F), C L/ F, a n d V z/ F. 
F oll o wi n g I V d osi n g of [1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci), t he f oll o wi n g P K 
para meters will be calc ulate d, w he ne ver p ossi ble,  base d o n t he plas ma c o nce ntrati o ns of 
Pr ot oc ol A me n d me nt [ADDRESS_663904] 2 0 1 8 Pa ge 1 4 of 6 0 [1 4C]- L O X O- 2 9 2:  C ma x, Tma x, A U C last, A U C 0-, z, t1/ 2, s yste mic cleara nce ( C L), v ol u me 
of distri b uti o n d uri n g t he ter mi nal p hase ( V z), a n d v ol u me of distri b uti o n at stea d y state 
( Vss).  
T he f oll o wi n g P K para meters will b e calc ulate d, w he ne ver p ossi ble, f or eac h s u bj ect 
base d o n t he uri ne c o nce ntrati o ns of L O X O - 2 9 2, [1 4C]- L O X O- 2 9 2, a n d t otal 
ra di oacti vit y:  A e u, C u m A e u, r e nal cleara nce ( C L R; L O X O- 2 9 2 a n d [1 4C]- L O X O- 2 9 2 
o nl y ), %f e u, a n d C u m %f e u. 
T he f oll o wi n g P K para meters will b e calc ulate d, w he ne ver p ossi ble, f or eac h s u bj ect base d o n t he fecal c o nce ntrati o ns of t otal ra di oacti vit y:  A
ef, C u m A ef, %f ef, a n d C u m 
% fef. 
I n P arts 1 a n d 2, t he P K para meters f or rele va nt meta b olites of L O X O- 2 9 2 ma y be 
calc ulate d, as dee me d a p pr o priate, base d o n plas ma, uri ne, a n d fecal c o nce ntrati o n le vels. 
Sa m ple Size: T he sa m ple sizes c h ose n f or Parts [ADDRESS_663905] u d y were base d o n prece d e nt set b y 
ot her A M E a n d a bs ol ute bi oa v aila bilit y s t u dies of si milar nat ure a n d were n ot base d o n 
p o wer calc ulati o ns. 
Statistical Met h o ds: F or P arts 1 a n d 2, d escri pti ve statistics ( n u m ber of o bser vati o ns, arit h metic mea n, 
sta n dar d de viatio n, me dia n, mi ni m u m, ma xi m u m, ge o metric mea n, a n d ge o metric c o efficie nt of variati o n) will be calc ulate d f or t he P K para meters. N o f or mal statistical 
P K  a nal yses are pla n ne d. F or P arts [ADDRESS_663906] 2 0 1 8 Pa ge 1 5 of 6 0 2  I N T R O D U C TI O Na 
Please refer t o t he I n v esti gat or’s Br oc h ure  (I B)[ADDRESS_663907] u dies, a n d a d v erse e ve nt ( A E) pr ofile of 
t he i n vesti gati o nal me dici nal pr o d uct. 
2. 1  B ac k gr o u n d 
L O X O- 2 9 2 is a s mall m olec ule sele cti ve i n hi bit or of t he rearra n ge d d uri n g tra nsfecti o n ( R E T) 
rece pt or t yr osi ne ki nase desi g ne d t o c o m petiti vel y bl oc k t he a de n osi ne tri p h os p hate bi n di n g site of t he ki nase. L O X O- [ADDRESS_663908] 2 5 0-f ol d m ore sele cti ve f or R E T t ha n f or 9 8 % of [ADDRESS_663909] u dies 
P har mac ol o g y safet y of L O X O- 2 9 2 w as e val u ate d i n a G o o d La b orat or y Practice ( G L P) i n vitr o 
assa y f or h u ma n et her-a- g o- g o relate d ge ne ( h E R G) acti vit y, i n a G L P i n vi v o st u d y i n c o nsci o us 
tele metr y-i nstr u me nte d mi ni pi [INVESTIGATOR_14107], a n d i n a G L P [ADDRESS_663910] u d y ( wit h 
electr ocar di o gra m [ E C G] m o nit ori n g) i n mi ni pi [INVESTIGATOR_14107]. L O X O- 2 9 2 ha d a half m a xi mal i n hi bit or y c o nce ntr ati o n val ue (I C
5 0) of 1. 1 μ M i n t he G L P h E R G assa y, w hic h is a p pr o xi matel y 1 7 - a n d 
9-f ol d hi g h er t ha n t he pre dicte d ma xi m u m u n b o u n d c o nce ntr ati o n at t he cli nical d ose of 8 0 m ga n d 1 6 0 m g, res pecti vel y, t wice dail y ( BI D). T h ere were n o L O X O- 2 9 2-rel ate d c ha n ges i n a n ycar di o vas c ular e n d p oi nts i ncl u di n g Q T i nter val c orrecte d f or heart rat e ( Q T c) at d oses u p t o1 2 m g/ k g i n t he safet y p h ar mac ol o g y car di o vas c u lar st u d y i n c o nsci o us mi ni pi [INVESTIGATOR_14107]. F urt h er m ore,t here were n o L O X O- [ADDRESS_663911] u d y i nmi ni pi [INVESTIGATOR_22736] t he hi g h d os e of 1 2 m g/ k g. T o get h er, t hese data i n dic ate t hat L O X O- 2 9 2 has a l o wris k of i n d uci n g d ela ye d ve ntric ular re p olarizati o n, pr ol o n g ati o n of t he Q Tc i nter val, a n d
u nsta ble arr h yt h mias.
A d mi nistrati o n of L O X O- 2 9 2 at si n gle d os es u p t o 4 5 m g/ k g i n male rats h a d n o effect o n 
res pi[INVESTIGATOR_1305] y f u ncti o n. 
a I nf or mati o n s u p plie d b y t he S p o ns or. 
Pr ot oc ol A me n d me nt [ADDRESS_663912] u dies of L O X O- 2 9 2 t hat w ere c o n d ucte d i n t he rat a n d mi ni pi g, t he pri mar y 
pat h ol o gic fi n di n gs f or b ot h s pecies were i n t he t o n g ue, p a ncreas, b o n e marr o w, a n d l y m p h oi d tiss ues; w hile t he gastr oi ntesti nal ( GI) tract a n d o varies were tar get tiss ues i n mi ni pi g. Ot her tar get tiss ues i de ntifie d i n t he rat i ncl u de d: m ulti-tiss ue mi neralizati o n, p h yseal cartila ge, i ncis or 
teet h, l u n g, Br u n ner’s gla n d, a n d p ossi bl y li ver. Assess me nt of d oses ass oci ate d wit h 
m ori b u n dit y/ d eat h r e veal e d a stee p d os e res p o ns e c ur ve f or b ot h s pecies. 
L O X O- 2 9 2 w as n ot m uta ge ni c i n t he G L P b acterial m utati o n assa y. L O X O- 2 9 2 was n ot f o u n d t o 
be p h ot ot o xic w he n e val uate d i n a n i n vitr o ne utr al re d u pta ke p h ot ot o xicit y assa y. 
Base d o n precli nic al p har mac ol o g y e x peri me nts wit h  h u ma n ca ncer cells i n vitr o a n d i n m uri ne 
x e n o graft m o dels, mea ni n gf ul i n hi biti o n of R E T i n t u m ors is e x pecte d t o be ac hie v a ble wit h oral d osi n g re gi me ns ≥  4 0 m g/ da y. 
Base d o n t h e n o ncli nical pr ofile, i ncl u di n g res ult s fr o m a ni mal t o xic ol o g y st u dies, t he oretical 
ris ks of h u ma n e x p os ure t o L O X O- 2 9 2 i ncl u de t h e f oll o wi n g: l oss of a p p etite, decrease i n b o d y 
wei g ht, i ncreas e i n t otal w hite bl o o d cells, ne utr o p hils, a n d m o n oc ytes, d ecreas e i n al b u mi n, i ncreas e i n gl o b uli n, de crease d al b u mi n: gl o b uli n rati o, decrease i n t otal pr otei n, i ncreas e d b o d y te m perat ur e, let har g y, i n creas e i n c h olester ol a n d tri gl yceri des, i ncrease i n p h os p h or us, c ha n ges i n taste se nsati o n a n d/ or de vel o p me nt of xer ost omia, GI s y m pt o ms/si g ns: n a usea, v o miti n g, l o ose st o ols, a b d o mi nal disc o mf ort, decreases i n r e d cell mass (re d bl o o d cells, he m o gl o bi n, he mat ocrit) a n d retic ul oc yt es, decrease i n platel ets, i ncreas es i n li ver f u ncti o n tests (al kali ne p h os p hatase [ A L P], as partate a mi n otra nsf eras e [ A S T], a n d ala ni ne a mi n otra nsferase [ A L T]). 
L O X O- 2 9 2 has b ee n gi v e n orall y a n d i ntra v e n o usl y (I V) t o mice, rats, d o gs, mi ni pi [INVESTIGATOR_14107], a n d 
m o n ke y. L O X O- [ADDRESS_663913] u dies a n d 
p har mac o ki netic ( P K) st u dies s u g gest t hat t he P K e x p os ure of L O X O- 2 9 2 ma y b e re d u ce d b y 
pr ot o n p u m p i n hi bit ors a n d ot her a ntaci ds. L O X O - 2 9 2 a p pears t o be meta b olize d pri maril y b y c yt o c hr o me P 4 5 0 ( C Y P) [ADDRESS_663914] d ose a d mi nistere d. As of t he J a n uar y 5, 2 0 1 8, n o d ose-li miti n g t o xicities ( D L Ts) ha ve bee n re p orte d. Treat me nt-e mer ge nt A Es ( T E A Es) occ urri n g i n ≥  1 0 % of patie nts were: 
fati g u e ( 1 6 %), diarr h ea ( 1 6 %), a n d d ys p nea ( 1 2 %). T he maj orit y of T E A Es were Gra d es 1 or 2 
a n d n o ≥  Gra d e [ADDRESS_663915] u g. 
L o x o O nc ol o g y has als o i nitiate d 3 I nstit uti o nal Re vie w B o ar d (I R B)-a p pr o ve d, F o o d a n d Dr u g 
A d mi nistrati o n ( F D A)-all o we d si n gle p atie nt pr ot oc ols ( L O X O- R E T- 1 7 0 0 2, L O X O- R E T-1 7 0 0 3, a n d L O X O- R E T- 1 7 0 0 4) t o pr o vi de access t o L O X O- [ADDRESS_663916] u g f or t h ese p atie nts. 
As of Fe br uar y 9, 2 0 1 8, P K data were a vaila bl e fr o m patie nts (fr o m t he L O X O- R E T- [ADDRESS_663917] u d y). L O X O- 2 9 2 is a bs or be d aft er oral a d mi nistrati o n wit h a ti me t o ma xi m u m o bser ve d 
c o nce ntr ati o n ( T
ma x) of a p pr o xi matel y 2 h o urs. Alt h o u g h t he P K sa m pli n g of L O X O- 2 9 2 was n ot 
l o n g e n o u g h t o a d e q uatel y c h aracteriz e area u n d er t he c o nce ntr ati o n-ti me c ur ve ( A U C) fr o m ti me [ADDRESS_663918] q ua ntifia ble c o n ce ntr ati o n ( A U C
0- ∞), t he half-life was esti mate d t o 
be at least [ADDRESS_663919] u d y t o deter mi ne t he a bs or pti o n, meta b olis m, a n d e x creti o n 
( A M E) ki netics of L O X O- 2 9 2 a n d t o deter mi ne an d c haracteriz e meta b olit es prese nt i n plas ma, uri ne, a n d feces i n healt h y male s u bjects f oll o wi n g a si n gle oral d ose of 1 6 0 m g of [
1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 4 0 μ Ci) a d mi nistere d as a n oral s ol uti o n. Bl o o d, plas ma, uri ne, 
a n d feces sa m pli n g will be c o n d ucte d u ntil at least Da y [ADDRESS_663920] u d y o bje cti ves base d o n t he k n o w n cli nical P K of L O X O- 2 9 2. 
Part 2 uses a n I V micr otracer m et h o d t o deter mi ne t he a bs ol ute bi oa vaila bilit y of L O X O- 2 9 2 
f oll o wi n g a si n gle oral d ose of 1 6 0 m g of L O X O- 2 9 2 a n d a n I V micr otracer d ose of < 1 0 0 μ g of [
1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci). T he I V mi cr otracer met h o d all o ws f or si m ulta ne o us oral 
a n d I V d osi n g i n t he sa m e s u bjects, w hic h is e x pecte d t o res ult i n less varia bilit y i n a bs ol ute bi oa vaila bilit y esti mates. A bs ol ute bi oa vaila bilit y will be deter mi ne d b y c o m pari n g t he pl as ma e x p os ure of L O X O- 2 9 2 f oll o wi n g oral d osi n g wit h t he plas ma e x p os ure of [
1 4C]- L O X O- 2 9 2 
f oll o wi n g I V d osi n g. T h e I V d ose of [1 4C]- L O X O- 2 9 2 will be a d mi nistere d s o t hat pea k plas ma 
c o nce ntr ati o ns of [1 4C]- L O X O- 2 9 2 occ ur a p pr o xi matel y at t he T ma x of L O X O- 2 9 2 f oll o wi n g oral 
d osi n g. Beca use it i ncl u des uri ne a n d feces s a m pli n g, Part 2 will als o pr o vi de a d diti o nal data a b o ut t he e x creti o n pr ofil e of L O X O- 2 9 2. A nal ysis of uri ne c o n ce ntrati o ns of L O X O- 2 9 2, [
1 4C]- L O X O- 2 9 2, a n d t otal ra di oacti vit y will all o w f or t he det er mi nati o n of re nal cleara nce 
( C L R) a n d t he p erce nta ge of L O X O- 2 9 2 e x crete d u nc ha n ge d i n t he uri n e. A nal ysis of t otal 
ra di oacti vit y i n fecal sa m ples f oll o wi n g I V d osi n g will pr o vi de i nf or mati o n a b o ut t he e xte nt of fecal e x creti o n of L O X O- 2 9 2. 
Fe male s u bjects will be e x cl u de d t o ali g n wit h re g ulat or y g ui da n ce. T h e “as l o w as (is) 
reas o na bl y ac hie v a ble” ( A L A R A) pri nci ple prescri be d b y b ot h t he F D A a n d N uclear R e g ulat or y C o m missi o n ( 2 0 0 7) rec o m me n ds t hat ra diati o n e x p os ure t o s u bjects s h o ul d be ke pt A L A R A; t heref ore, if n o s pecific reas o n e xists t o i ncl u de fe males (ie, n o a v aila ble data s u g gest meta b olis m of t he st u d y dr u g is differe nt i n fe mal es vers us males), t h e n t he ra diati o n e x p os ure t o fe male s u bjects s h o ul d be ke pt at zer o p ote ntial b y n ot i ncl u di n g fe mal es i n ra di oacti vit y st u dies 
a n d o nl y e nr olli n g a n d d osi n g male s u bjects. 
2. [ADDRESS_663921] u d y ( L O X O- R E T- 1 7 0 0 1) , 1 6 0 m g of L O X O- 2 9 2 d ose d BI D was w ell t olerate d a n d n o D L Ts w ere det er mi ne d; t heref ore, a si n gle [ADDRESS_663922] u d y o bjecti ves wit h mi ni mal ris k t o s u bjects. 
T he pla n ne d ra di oacti ve d ose of ~ 4 0 μ Ci ( wit h a n all o wa ble ma xi m u m of 4 5 μ Ci) of 
[
1 4C]- L O X O- [ADDRESS_663923] u dies i n h u ma ns, acc or din g t o t he U nite d States ( U S) C o de of Fe deral Re g ulati o ns ( C F R) g o v er ni n g Pr otecti o n of H u m a n S u bjects, Ra di oacti ve Dr u gs f or Cert ai n Researc h Uses ( 2 1 C F R 3 6 1. 1). It is e x pecte d t h at t he pla n ne d ra di o acti ve d ose will pr o vi de a s ufficie nt ra di o acti ve si g nal f or t otal ra di oa cti vit y c o u nti n g a n d q u a ntitati ve ra di o pr ofili n g of [
1 4C]- L O X O- 2 9 2 i n bl o o d, plas ma, a n d e x creta ( uri ne a n d feces) wit h mi ni mal ra diati o n ris k t o 
s u bjects. 
T he ra di oa cti ve d ose of ~ 1 μ Ci of [1 4C]- L O X O- 2 9 2 i n Part 2 is o nl y a b o ut 1 % of t he ra di o acti ve 
d ose pla n ne d f or Part 1 a n d will prese nt mi ni mal ra diati o n ris k t o healt h y s u bjects. T he l o w 
le vels of ra di oa cti vit y pla n ne d f or Part 2 will necessitate t he use of accel erat or mass 
s pectr o metr y ( A M S) as a hi g hl y se nsiti ve a nal ytical tec h ni q ue f or q ua ntif yi n g t he ra di oacti vit y i n 
plas ma, uri ne, a n d fecal sa m ples. T he ra di o acti ve d ose of ~ [ADDRESS_663924] u d y o bjecti ves of Part 2 wit h mi ni mal ra diati o n e x p os ure ris k t o healt h y s u bjects. 
3  S T U D Y O B J E C TI V E S 
Part 1: 
T he pri mar y o bje cti ves of Part [ADDRESS_663925] u d y are: 
 T o deter mi ne mass bal a n ce a n d r o ut es of eli mi nati o n of [
1 4C]- L O X O- 2 9 2 f oll o wi n g oral 
a d mi nistrati o n of a si n gle 1 6 0- m g ( ~ 4 0 μ Ci) ra di ola bele d d ose of L O X O- 2 9 2 i n healt h y 
male s u bjects 
 T o assess t he P K of a si n gle d ose of L O X O- 2 9 2 usi n g [1 4C]- L O X O- 2 9 2 
 T o deter mi ne t he w h ol e bl o o d a n d plas ma c o nce ntrati o ns of t otal ra di oacti vit y 
 T o deter mi ne t he uri n ar y a n d fecal rec o ver y of t otal ra di oacti vit y  T o c haracteriz e a n d i d e ntif y meta b olites of [
1 4C]- L O X O- [ADDRESS_663926] u d y is: 
 T o assess t he safet y a n d t olera bilit y of [1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 4 0 μ Ci). 
 
Part 2: 
T he pri mar y o bje cti ves of Part [ADDRESS_663927] u d y are: 
 T o deter mi ne t he a bs ol ute bi oa vaila bilit y of L O X O- 2 9 2 f oll o wi n g a si n gle oral d ose of 
1 6 0 m g of L O X O- 2 9 2 al o n g wit h a n I V d ose of < 1 0 0 μ g of [1 4C]- L O X O- 2 9 2 
(c o ntai ni n g ~ 1 μ Ci) 
 T o e val uate t he P K of L O X O- 2 9 2 f oll o wi n g oral a n d I V d osi n g 
 T o e val uate t he uri nar y e x creti o n of L O X O- 2 9 2 f oll o wi n g oral d osi n g a n d of 
[1 4C]- L O X O- 2 9 2 f oll o wi n g I V d osi n g 
 T o e val uate t he fecal rec o ver y of t otal ra di o acti vit y f oll o wi n g I V d osi n g of 
[1 4C]- L O X O- [ADDRESS_663928] u d y is: 
 T o assess t he safet y a n d t olera bilit y of L O X O- [ADDRESS_663929] u d y of 
[1 4C]- L O X O- 2 9 2. S u bje cts i n Part 1 will n ot partic i pate i n Part 2, n or will s u bjects i n Part 2 
partici pate i n Part 1. Part 1 a n d Part 2 are i n de pe n d e nt of eac h ot her a n d d o n ot nee d t o be 
c o n d ucte d i n se q ue ntial or der. 
Part 1 is desi g ne d t o e v al uate t he A M E ki netics of L O X O- 2 9 2, t o i de ntif y a n d c haracteriz e 
meta b olites of L O X O- 2 9 2, a n d t o assess t he safet y a n d t olera bilit y of [1 4C]- L O X O- 2 9 2. S u bje cts 
i n Part 1 will be a d mi nistere d a si n gle oral d ose of 1 6 0 m g of [1 4C]- L O X O- 2 9 2 (c o ntai ni n g 
~ 4 0 μ Ci) as a n oral s ol uti o n. I n or der t o c o m plete 6 s u bjects, 6 will be e nr olle d ( differe nt s u bjects fr o m t h ose parti ci pati n g i n Part 2), al o n g wit h 2 alter nates (t o be d ose d i n t he e ve nt t hat d osi n g is u ns uccessf ul f or a n y of t he i nitial 6 s u bjects). I n t he e ve nt of earl y wit h dra wal of a n y 
s u bjects after t h e alter nate s u bjects are rel eased, re place me nt s u bjects ma y be e nr olle d at t he 
discreti o n of t he S p o ns or. 
Part 2 is desi g ne d t o det er mi ne t he a bs ol ute bi oa v aila bilit y of L O X O- 2 9 2, t o e val uate t he uri n ar y 
e x creti o n of L O X O- 2 9 2 a n d [
1 4C]- L O X O- 2 9 2, t o e val uate t he fecal e x creti o n of 
[1 4C]- L O X O- [ADDRESS_663930] 2 0 1 8 Pa ge 2 1 of 6 0 
 2 h o urs later b y a si n gle d ose of < 1 0 0 μ g of [1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci) a d mi nistere d 
as a n I V p us h o v er a p pr o xi matel y 2 mi n utes. I n or der t o c o m plete 6 s u bjec ts, 6 will be e nr olle d 
( differe nt s u bjects fr o m t h ose partici pati n g i n Part 1), al o n g wit h 2 alter nat es (t o be d ose d i n t he e ve nt t hat d osi n g is u ns u ccessf ul f or a n y of t h e i nitial 6 s u bjects). I n t he e v e nt of earl y wit h dra wal of a n y s u bjects after t he alter nate s u bj ects are rele ase d, re place me nt s u bjects ma y b e e nr olle d at t he discreti o n of t he S p o ns or. 
T he start of t he st u d y is d efi ne d as t he earliest d ate  a s u bject w h o is e nr olle d i n eit her part of t he 
st u d y si g ns a n I nf or me d C o nse nt F or m (I C F). A s u bject w h o c o m pletes s ufficie nt L O X O- 2 9 2, [
1 4C]- L O X O- 2 9 2 ( Part 2 o nl y), t otal ra di oacti vit y, a n d meta b olite ( Part 1 o nl y) sa m pli n g pri or t o 
Cli nic Disc har ge is c o nsi dere d t o ha v e c o m plete d t he st u d y. T he e n d of t he st u d y is defi ne d as 
t he latest date a s u bject recei ves t he Safet y F oll o w- u p Call. T he pla n ne d d urati o n of st u d y 
c o n d uct f or Part [ADDRESS_663931] u d y Desi g n Sc he m atic:  P art 1 
Scree ni n g C hec k -i n D osi n ga L O X O- 2 9 2 a n d T ot al 
R a di o acti vit y 
C o nce ntr ati o ns , a n d M etI D 
S a m pli n g Cli nic 
Disc h ar g eb S afet y F oll o w- u p 
C allc 
Da ys -2 9 t o 
- 2 Da y - 1 Da y 1 Da y 1 t o Cli nic Disc har ge Da ys 8 t o 2 2 A p pr o xi matel y 
7  da ys after Cli nic 
Disc har ge  
 Cli nic C o nfi ne me nt  
MetI D = met a b olite pr ofili n g a n d i d e ntificati o n 
a  Si n gle oral d ose of 1 6 0 m g of [1 4C]- L O X O- 2 9 2 ( ~ 4 0 μ Ci) a d mi nistere d as a n oral s ol uti o n f oll o wi n g a n o ver ni g ht fast. 
b  S u bjects will be disc har ge d fr o m t h e Cli nical Researc h U nit ( C R U) starti n g o n Da y 8 if ≥  9 0 % of t h e ra di oacti ve d ose is 
rec o vere d a n d ≤  1 % of t h e ra di oacti ve d ose per da y is rec o vere d i n e xcreta ( uri n e a n d feces) f or [ADDRESS_663932] u d y Desi g n Sc he m atic:  P art 2 
Scree ni n g C hec k- i n D osi n ga L O X O- 2 9 2, 
[1 4C]- L O X O- [ADDRESS_663933]. A si n gle i ntra ve n o us 
(I V) d ose of < 1 0 0 μ g of [1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci of ra di oacti vit y) will be a d mi nistere d b y I V p us h 2 h o urs after 
t h e oral d ose. 
b  S u bjects will recei ve a Safet y F oll o w- u p Call a p pr o xi matel y 7 da ys after Cli nic Disc har ge. 
 
Part 1: After a Scree ni n g p eri o d of u p t o 2 8 da ys, s u bj ects will c hec k i n t o t he Cli nical Researc h U nit ( C R U) o n Da y - [ADDRESS_663934] 8 h o urs, s u bjects will recei ve a si n gl e oral d ose of 1 6 0 m g of [
1 4C]- L O X O- 2 9 2 (c o nt ai ni n g ~ 4 0 μ Ci) a d mi nistere d as a n oral s ol uti o n. 
S u bjects will be c o nfi ne d at t he C R U fr o m t he ti me of C hec k-i n u ntil Cli nic Disc har ge ( bet wee n Da ys 8 a n d 2 2). After c o m pleti n g disc har ge pr oce d ure s, s u bjects will be disc har ge d fr o m t he C R U as earl y as D a y 8 a n d u p t o Da y 2 2, pr o vi de d rec o ver y of ra di oacti vit y has reac he d t he f oll o wi n g t hres h ol d val u es:  
 ≥  9 0 % of t he ra di o acti ve d ose is rec o vere d, a n d  
 ≤  1 % of t he ra di o acti ve d ose per da y is r ec o v ere d i n e x creta ( uri ne a n d feces) f or 
3 c o nsec uti ve da ys o n w hic h a fecal sa m ple is c ollecte d.   
Sa m ple c ollecti o n a n d c o nfi ne me nt will c o nti n ue u ntil disc har ge criteria are met or t he ma xi m u m 
sta y is reac h e d, u nless ot her wise a gree d u p o n b y t he S p o ns or a n d I n vesti gat or ( or desi g nee). S u bjects will recei ve a Safet y F oll o w- u p Call  a p pr o xi matel y 7 d a ys after Cli nic Disc har ge. 
Safet y will be m o nit ore d wit h A E i n q uiries, cli nical la b orat or y e val uati o ns ( A p pe n di x A ), vital 
si g ns meas ur e me nts, [ADDRESS_663935] u d y.  Sa m ples f or deter mi nati o n of L O X O- 2 9 2 c o nce ntr ati o ns i n plas ma, t otal ra di oacti vit y 
c o nce ntrati o ns i n plas ma, w h ole bl o o d, uri ne, a n d feces, a n d f or m eta b olite 
pr ofili n g/c h aracteriz ati o n will be o btai ne d t hr o u g h at least [ADDRESS_663936] d ose ( Da y 8), a n d p ossi bl y u p t o [ADDRESS_663937] d ose ( Da y 2 2). A Sc he d ule of Assess me nts f or Part [ADDRESS_663938] ma y b e c o nsi dere d n ot e v al ua ble a n d t he Me di cal M o nit or ( or desi g nee) s h o ul d be c o ntacte d i m m e diatel y f or f urt her i nstr u cti o ns a n d t o deter mi ne if t he s u bject s h o ul d c o nti n ue t he st u d y. All v o mit us c ollecte d will be st ore d f or p ossi ble a n al ysis.  
Part 2: 
After a Scree ni n g p eri o d of u p t o [ADDRESS_663939] 8 h o urs, s u bjects will recei ve a si n gle oral d ose of 1 6 0 m g of L O X O- 2 9 2 as 2 x 8 0- m g ca ps ules f oll o we d 2 h o urs later b y a si n gle d os e of < 1 0 0 μ g of [
1 4C]- L O X O- 2 9 2 (c o ntai ni n g ~ 1 μ Ci) a d mi nistere d as a n I V p us h o v er a p pr o xi matel y 2 mi n utes. 
S u bjects will be c o nfi ne d at t he C R U fr o m t he ti me of C hec k-i n u ntil Da y 9 a n d will be disc har ge d fr o m t he C R U after c o m pleti n g all disc har ge pr oce d ures. S u bje cts will recei ve a Safet y F oll o w- u p Call a p pr o xi matel y 7 d a ys after Cli nic Disc har ge.  
As i n Part 1, safet y will be m o nit ore d wit h A E i n q uiries, cli nical la b orat or y e val uati o ns 
(A p pe n di x A ), vital si g ns meas ure me nts, [ADDRESS_663940] u d y.  
Sa m ples f or deter mi nati o n of plas ma a n d uri ne c o nce ntrati o ns of L O X O- 2 9 2 a n d 
[
1 4C]- L O X O- [ADDRESS_663941] d ose ( Da y  9). A Sc he d ule of Assessme nts f or Part [ADDRESS_663942] u g i n healt h y a d ult male s u bjects t o s u p p ort its f urt h er de vel o p me nt a n d re gistrati o n. Part 1 will als o all o w f or i de ntificati o n a n d c haracterizatio n of a n y m eta b olites of L O X O- 2 9 2 t hat are pr o d uce d f oll o wi n g oral d osi n g.  
Part 2 is desi g ne d t o det er mi ne t he a bs ol ute bi oa v aila bilit y of L O X O- 2 9 2 b y c o m p ari n g its 
plas ma e x p os ure f oll o wi n g oral d osi n g t o t he plas ma e x p os ure of [
1 4C]- L O X O- 2 9 2 f oll o wi n g I V 
micr otracer a d mi nistrati o n. T he I V micr otr ace r met h o d all o ws f or si m ulta ne o us oral a n d I V d osi n g i n t he sa me s u bjects, w hic h is e x pecte d t o res ult i n less varia bilit y i n a bs ol ute bi oa vaila bilit y esti mates. T he I V d ose of [
1 4C]- L O X O- 2 9 2 will be a d mi nistere d s o t hat pe a k 
plas ma c o nce ntrati o ns of [1 4C]- L O X O- [ADDRESS_663943] 2 0 1 8 Pa ge 2 4 of 6 0 
 A nal ysis of uri ne c o n ce ntrati o ns of L O X O- 2 9 2, [1 4C]- L O X O- 2 9 2, a n d t otal ra di oacti vit y will 
all o w f or deter mi nati o n of C L R a n d f or t he perce nt a ge of L O X O- 2 9 2 e x crete d u nc ha n ge d i n 
uri ne. A nal ysis of t otal ra di oacti vit y i n feces will pr o vi de i nf or mati o n a b o ut t he e xte nt of fecal 
e x creti o n of L O X O- 2 9 2. 
I n Part 2, a micr otracer ( ~ 1 μ Ci) of [1 4C]- L O X O- [ADDRESS_663944] u d y me as ures are o bje cti ve o utc o mes (e g, P K 
para meters, t otal ra di oa cti vit y i n sel ect bi ol o gi cal matrices, meta b olite 
pr ofili n g/c h aracteriz ati o n). C o n d ucti n g t he st u d y i n healt h y s u bjects will all o w t he e val uati o n of 
L O X O- [ADDRESS_663945] u d y. Safet y e v al uati o ns m a y b e re peate d at t he I n v esti gat or’s ( or desi g nee’s) discreti o n. 
Eac h s u bject is all o we d t o partici pate i n o nl y o ne part of t he st u d y. I n or der t o c o m plete 
[ADDRESS_663946] or y a n d all scree ni n g e v al uati o ns f or p ote ntial s u bjects pri or 
t o e nr oll me nt. Pri or t o d osi n g, t he S p o ns or will pr o vi de a p pr o val of s u bje cts selecte d f or e nr oll me nt b y t he I n vesti gat or ( or desi g n ee).  
5. [ADDRESS_663947] u d y: 
1.  Males of a n y race bet wee n 1 8 a n d 5 5 years of a ge, i ncl usi ve, at Scree ni n g 2.  B o d y mass i n de x bet wee n 1 8. 5 a n d 3 2. 0 k g/ m
2, i ncl usi ve, at Scree ni n g 
3.  I n g o o d h ealt h, deter mi ne d b y n o cli nicall y si g nifi ca nt fi n di n gs fr o m me dic al 
hist or y, p h ysical e x a mi nati o n, [ADDRESS_663948] 2 0 1 8 Pa ge 2 5 of 6 0 
 la b orat or y e v al uati o ns (A p pe n di x A ) at Scree ni n g or C hec k-i n as assesse d b y t he 
I n v esti gat or ( or desi g n ee) 
4.  S u bjects will be s ur gic all y sterile f or at  le ast [ADDRESS_663949] u d y: 
1.  Si g nifica nt hist or y or cli nical ma nifestati o n of a n y meta b olic, aller gic, i nf ecti o us, 
der mat ol o gi cal, he p atic, re nal, he mat ol o gical, p ul m o nar y, car di o vasc ular, GI, 
ne ur ol o gi cal, res pi[INVESTIGATOR_1305] y, e n d ocri ne, or ps yc hiatric dis or der, as det er mi ne d b y t he I n v esti gat or ( or d esi g n ee) 
2.  Hist or y of si g nifica nt h y perse nsiti vit y, i nt olera n ce, or aller g y t o a n y dr u g 
c o m p o u n d, f o o d, or ot her s u bsta nce, u nless a p pr o ve d b y t h e I n vesti gat or ( or desi g nee) 
3.  Hist or y of st o ma c h or i ntesti nal s ur ger y or resecti o n t hat w o ul d p ote ntiall y alter 
a bs or pti o n a n d/ or e x creti o n of orall y a d mi nistere d dr u gs ( u nc o m plicate d a p pe n dect o m y a n d her ni a re pair will be all o we d)  
4.  Hist or y of c o n ge nital n o n he m ol ytic h y per bilir u bi ne mia (e g, Gil bert’ s 
s y n dr o me) 
5.  Has ha d a c h olec yste ct o m y 6.  Hist or y of alc o h olis m or dr u g/c h e mical a b us e wit hi n 2 years pri or t o C hec k-i n 7.  T y pic al alc o h ol c o ns u m pti o n of > 2 1 u nits per wee k f or males. O ne u nit of 
alc o h ol e q uals 1 2 oz ( 3 6 0 m L) beer, 1 ½ oz ( 4 5 m L) li q u or, or 5 oz ( 1 5 0 m L wi ne) 
8.  P ositi ve uri ne dr u g scree n (i ncl u di n g c o ti ni ne) at Scree ni n g, or p ositi ve uri ne dr u g 
scree n (i ncl u di n g c oti ni ne) or al c o h ol breat h test at C hec k-i n 
9.  P ositi ve he patitis pa nel a n d/ or p ositi v e h u ma n i m m u n o deficie nc y vir us ( HI V) test 
(A p pe n di x A ). S u bjects w h ose res ults are c o m pati ble wit h pri or i m m u niz ati o n a n d n ot i nfecti o n ma y be i ncl u de d at t h e discreti o n of t he I n vesti gat or ( or desi g nee) 
Pr ot oc ol A me n d me nt [ADDRESS_663950] 2 0 1 8 Pa ge 2 6 of 6 0 
 1 0.  Esti mate d creati ni ne cleara nce < 9 0 m L/ m i n at Scree ni n g or C hec k-i n, c alc ulate d 
usi n g t he C oc kcr oft- G a ult e q uati o n 
1 1.  A b n or mal li ver f u ncti o n tests ( L F Ts), as defi ne d b y A S T, A L T, A L P, a n d s er u m 
(t otal a n d direct) bilir u bi n, as well as a mylase a n d li pase a b o ve t he u p p er li mit of t he n or mal ra n ge at Scree ni n g or C hec k-in, u nless dee me d acce pta ble b y t h e I n v esti gat or ( or d esi g n ee) wit h pri or S p o ns or a p pr o val. Rec hec ks of L F Ts will be per mitte d u p t o [ADDRESS_663951] olic bl o o d press ure ( B P) is < 8 9 m m H g or > [ADDRESS_663952] olic B P is < 5 0 m m H g or > 8 9 m m H g, at Scree ni n g, C hec k-i n, or pri or t o d osi n g o n Da y 1 of Part 1 or Part 2, u nless dee me d acce pta ble b y t he I n v esti gat or ( or desi g nee) wit h pri or S p o ns or a p pr o val. Rec h ec ks of B P val u es will be per mitte d u p t o [ADDRESS_663953]. 
1 3.  S u pi [INVESTIGATOR_512904] e is < 5 0 b p m or > 9 9 b p m at Scree ni n g or C h ec k-i n, u nless 
dee me d acce pta ble b y t h e I n vesti gat or ( or desi g nee) wit h pri or S p o ns or a p pr o val. Rec hec ks of h eart rate will be per mitte d u p t o [ADDRESS_663954] u d y b ase d 
o n rec hec ke d h eart rates if t he I n vesti gat or a n d/ or t he S p o ns or dee m t hat t he res ults are n ot cli nicall y si g nifica nt a n d will n ot i m pact st u d y c o n d uct. 
1 4.  Car diac e x cl usi o ns: Hist or y or pres e nce of a n y of t he f oll o wi n g, dee me d cli nicall y 
si g nifica nt b y t he I n vesti gat or ( or desi g n ee) a n d/ or S p o ns or: 
o  hist or y or prese n ce of cli nicall y si g nifica nt car di o vasc ular dise ase:  
 m y ocar dial i nfarcti o n or cere br o vasc ul ar t hr o m b o e m b olis m wit hi n [ADDRESS_663955] oris  
 Ne w Y or k Heart Ass ociati o n Class ≥  [ADDRESS_663956] o me ( W olff- Par ki ns o n W hite s y n dr o me)
 
 arr h yt h mia (e x cl u di n g b e ni g n si n us arr h yt h mia) or hist or y of arr h yt h mia re q uiri n g m e dical i nter ve nti o n
 
 ve ntric ular d ysf u n cti o n or ris k fact ors f or T ors a des de P oi ntes (e g, heart fail ure, car di o m y o p at h y, fa mil y hist or y of L o n g Q T S y n dr o me)
 
Pr ot oc ol A me n d me nt [ADDRESS_663957] 2 0 1 8 Pa ge 2 7 of 6 0 
  si g nifica nt scree ni n g E C G a b n or malities:   
 Left b u n dle- bra nc h bl oc k  
 Sec o n d de gree atri o v e ntric ular ( A V) bl oc k, t y pe 2, or t hir d 
de gree A V bl oc k  
 Q T i nter val c orrecte d f or heart rate usi n g Fri d erici a’s met h o d  
( Q Tc F) is > 4 5 0 mse c 
o  E C G fi n di n gs dee me d a b n or mal wit h cli nical si g nifica nce b y t h e 
I n v esti gat or ( or desi g n ee) at Scree ni n g or C hec k-i n 
[ADDRESS_663958] u d y 
1 6.  E x p os ure t o si g nifica nt r a diati o n (e g, seri al x-ra y or c o m p ute d t o m o gra p h y sca ns, 
bari u m meal, c urre nt e m pl o y me nt i n a j o b re q uiri n g ra diati o n e x p os ure m o nit ori n g) wit hi n [ADDRESS_663959] 3 0 da ys or 5 half-li ves (if k n o w n), w hic he ver is l o n ger, pri or t o C hec k-i n  
1 8.  Use or i nte nti o n t o use a n y me dicati o ns/ pr o d ucts k n o w n t o alter dr u g A M E 
pr ocesses, i n partic ular str o n g i n d u cer s or i n hi bit ors of C Y P [ADDRESS_663960]. J o h n’s w ort, wit hi n 3 0 da ys pri or t o C hec k-i n, u nless dee m e d acce pta ble b y t he I n v esti gat or ( or desi g n ee) 
1 9.  Use or i nte nti o n t o use a n y prescri pti o n me dicati o ns/ pr o d ucts wit hi n 1 4 da ys pri or 
t o C hec k-i n, u nless dee m e d acce pta ble b y t he I n vesti gat or ( or desi g nee) 
2 0.  Use or i nte nti o n t o use sl o w-rele ase me dicati o ns/ pr o d ucts c o nsi dere d t o still be 
acti ve wit hi n 1 4 da ys pri or t o C hec k-i n, u nless de e me d acce pta ble b y t h e I n v esti gat or ( or d esi g n ee) 
2 1.  Use or i nte nti o n t o use a n y n o n prescri pti o n me dicati o ns/ pr o d ucts i ncl u di n g 
vita mi ns, mi nerals, a n d p h yt ot hera pe utic/ h er bal/ pla nt- deri ve d pre parati o ns wit hi n 7 da ys pri or t o C hec k-i n, u nless dee me d acce pta bl e b y t h e I n vesti gat or ( or desi g nee) 
2 2.  C o ns u m pti o n of f o o ds a n d be vera ges c o ntai ni n g p o p p y see ds, gra p efr uit, or 
Se ville ora n ges fr o m 7 d a ys pri or t o C hec k-i n  
2 3.  C o ns u m pti o n of alc o h ol-, caffei ne-, or  xa nt hi ne-c o ntai ni n g f o o ds a n d b e vera ges 
fr o m 7 2 h o urs pri or t o C hec k-i n, u nless dee me d acce pta bl e b y t he I n vesti gat or ( or desi g nee) 
[ADDRESS_663961] 
3 0.  S u bjects w h o, i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or ( or desi g n ee), s h o ul d n ot 
partici pate i n t his st u d y. 
5. [ADDRESS_663962] u d y at a n y ti me a n d f or a n y 
reas o n. T he I n vesti gat or ( or desi g nee) or S p o ns or ma y re m o ve a s u bj ect fr o m t he st u d y if, i n t he I n v esti gat or’s ( or desi g nee’s) or S p o ns or’s o pi [INVESTIGATOR_9384] o n, it is n ot i n t he best i nterest of t he s u bject t o c o nti n ue t he st u d y. S u bje cts ma y b e wit h dra w n d u e t o t he f oll o wi n g: c h a n ge i n c o m plia nce wit h i ncl usi o n/e x cl usi o n criteri o n t hat is cli nicall y rele v a nt a n d affects s u bje ct safet y, o cc urre n ce of A Es, i nta ke of n o n per mitte d c o nc o mita nt me dicat i o n t hat mi g ht affect s u bject safet y or st u d y assess me nts/ o bjecti ves, etc. N otificati o n of wit h dr a wal will i m me diatel y b e ma de t o t he S p o ns or’s St u d y M o nit or. I n case of wit h dra w al of st u d y partici p ati o n, eff orts will be ma de t o perf or m all fi n al st u d y da y ass ess me nts ( Ta ble 6- 1 a n d Ta ble 6- 2). T he d ate t he s u bject is wit h dra w n fr o m t he st u d y a n d t h e reas o n f or wit h dra wal will be rec or de d o n t he s u bject’s electr o nic Cas e Re p ort F or m (e C R F). All wit h dra w n  s u bjects will be f oll o we d u ntil res ol uti o n of 
all t heir A Es or u ntil t he u nres ol ve d A Es are j u d ge d b y t h e I n vesti gat or ( or desi g nee) t o ha v e 
sta bilize d.  T he e ntire st u d y ma y be disc o nti n ue d at t he discreti o n of t he I n v esti gat or ( or desi g n ee) or S p o ns or base d o n t he occ urre nce of t he f oll o wi n g: 
 A Es n ot pre vi o usl y o bs er ve d f oll o wi n g a d mi nistrati o n of L O X O- [ADDRESS_663963] t o t heir 
nat ure, se v erit y, a n d/ or d urati o n 
 i ncreas e d fre q ue nc y a n d/ or se verit y a n d/ or d urati o n of k n o w n A Es 
 me dical or et hical reas o ns affecti n g t h e c o nti n ue d perf or ma n ce of t he st u d y  diffic ulties i n t he recr uit me nt of s u bjects 
 disc o nti n uati o n of cli nical de vel o p me nt of L O X O- [ADDRESS_663964] 2 0 1 8 Pa ge 3 0 of 6 0 
  
 T a ble 6- 1  Sc he d ule of Assess me nts:  P a rt 1 
 Scree ni n g C hec k-i n Tre at me nt C hec k- o ut F oll o w- u p 
E ve nts  D a ys - 2 9 
t o -2 D a y - 1 D a y 
1 D a y 
2 D a y 
3 D a y 
4 D a y 
5 D a y 
6  D a y 
7 Cli nic 
Disc h ar ge a  
( D a ys 8 t o 
2 2)/ E T b S af et y F oll o w- u p 
C all 
(a p pr o xi m atel y 
7  d a ys after Cli nic 
Disc h ar ge) 
I nf or me d C o nse nt X           
Assi g n me nt of Scree ni n g N u m ber X           
Re vie w of I ncl usi o n/ E xcl usi o n Criteria X X          
De m o gra p hic Data X           
Me dical Hist or y c X X          
Pri or Me dicati o ns X X          
Hei g ht, W ei g ht, B MI Calc ulati o n d X X          
Alc o h ol a n d Dr u g Scree n e X X          
Ser ol o g y T est ( H B c A b, H Bs A g, H C V A b, HI V) X           
C o nfi ne me nt t o C R U  X X X X X X X X X  
Assi g n me nt of S u bj ect N u m b er   X         
P h ysical E xa mi nati o n f X X        X  
Cli nical La b orat or y Safet y T ests (cli nical 
c he mistr y, T S H [ Scree ni n g o nl y], he mat ol o g y, 
a n d uri nal ysis) g X  X     X    X  
Pr ot oc ol A me n d me nt [ADDRESS_663965] 2 0 1 8 Pa ge 3 1 of 6 0 
  
  Scree ni n g C hec k-i n Tre at me nt C hec k- o ut F oll o w- u p 
E ve nts  D a ys - 2 9 
t o -2 D a y - 1 D a y 
1 D a y 
2 D a y 
3 D a y 
4 D a y 
5 D a y 
6  D a y 
7 Cli nic 
Disc h ar ge a  
( D a ys 8 t o 
2 2)/ E T b S af et y F oll o w- u p 
C all 
(a p pr o xi m atel y 
7  d a ys after Cli nic 
Disc h ar ge) 
Vital Si g ns ( oral te m perat ure, B P, heart rate, a n d 
res pi[INVESTIGATOR_1305] y rate) h X  X  X X X X X X X X  
1 2-lea d E C G i X X X       X  
L O X O- 2 9 2 A d mi nistrati o n 
( L O X O- 2 9 2 1 6 0 m g/ ~ 4 0 μ Ci [1 4C]- L O X O- 2 9 2)   X         
A E, S A E, a n d C o nc o mita nt M e dicati o ns a n d Pr oce d ures M o nit ori n g a n d R ec or di n g 
n        X--------------------------------------------------- O n g oi n g--------------------------------------------------- X 
A E = a d verse e ve nt; B MI = b o d y mass i n de x; B P = bl o o d press ur e; C R U = Cli nical Rese arc h U nit; E C G = electr ocar di o gra m; E T = ear l y ter mi nati o n; 
H B c A b = he p atitis B c ore a nti b o d y; H Bs A g = he p atitis B s urface a n ti ge n; H C V A b = he p atitis C vir us a nti b o d y; HI V = h u ma n i m m u n odeficie nc y vir us; S A E = seri o us a d verse e ve nt; T S H = t h yr oi d-sti m ulati n g h or m o ne. 
 C CI
Pr ot oc ol A me n d me nt [ADDRESS_663966] 2 0 1 8 Pa ge 3 2 of 6 0 
  
 a S u bj ects ma y be disc har ge d fr o m t he C R U starti n g o n Da y 8 if ≥  9 0 % of t he ra di oacti ve d ose is rec o vere d a n d ≤  1 % of t he ra di oacti ve d ose per da y is rec o vere d 
i n e xcreta ( uri ne a n d feces) f or [ADDRESS_663967] u g uri ne scree n ( w hic h i ncl u des c oti ni ne) will be c o n d ucte d at Scree ni n g a n d at C hec k-i n ( Da y - 1). A n alc o h ol breat h test wi ll be c o n d ucte d at C hec k-i n o nl y. 
f A c o m plete p h ysical e xa mi nati o n will be c o n d ucte d at Scre e ni n g a n d at Cli nic Disc har ge/ E T. A n a b bre viate d p h ysical e xa mi nati o n ( ge neral, heart, l u n gs, 
a b d o me n, a n d s ki n) will be c o n d ucte d at C hec k-i n. 
g E ver y atte m pt will be ma de t o e ns ure bl o o d sa m ples f or t he cli nical c he mistr y pa nel are c ollecte d f oll o wi n g a fast fr o m f o o d f or at least [ADDRESS_663968] e d at Scree ni n g, C hec k-i n, o n Da y 4, a n d at Cli nic Disc har ge/ E T. 
h S u bj ects are t o re mai n s u pi [INVESTIGATOR_050] f or at least 5 mi n utes pri or t o vital si g ns meas ure me nts. Vital si g ns will be o btai ne d at S cree ni n g; C hec k-i n; o n Da y [ADDRESS_663969] d ose; a n d dail y ( 2 4- h o ur i nter va ls) u p t o a n d i ncl u di n g da y of Cli nic Disc har ge/ E T. W he n sc he d ule d at t he s a me n o minal ti mes, p ost d ose vital si g ns meas ure me nts are t o be perf or me d pri or t o p ost d ose P K bl o o d dra ws (see Secti o n 6. 5 ), wit h bl o o d dra ws occ urri n g as cl ose t o t he n o mi nal ti mes as p ossi ble. 
i S u bj ects are t o r e mai n s u pi [INVESTIGATOR_050] f or at least [ADDRESS_663970] d ose, a n d at Cli nic Disc har ge/ E T.  W he n sc he d ule d at t he sa me n o mi nal ti mes, p ost d os e E C Gs are t o be perf or me d pri or t o p ostd ose vital si g ns meas ure me nts a n d P K bl o o d dra ws (see Secti o n 6. 5 ), wit h bl o o d dra ws occ urri n g as cl ose as p ossi ble t o t he n o mi nal ti mes.   
j  
 
 
 
  
 
 
   
n A Es, S A Es, a n d c o nc o mita nt me dicati o ns a n d pr oc e d ures will b e m o nit ore d a n d rec or de d t hr o u g h o ut t he st u d y fr o m t he ti me of si g n i n g t he i nf or me d c o nse nt, 
as descri be d i n Secti o n 6. 5. 1 , A p pe n di x C , a n d Secti o n 6. 3. 2 . A “ H o w D o Y o u Feel? ” A E i n q uir y will be perf or me d at Scree ni n g, C hec k-i n, eac h vital si g ns 
meas ure me nt, a n d d uri n g t he Safet y F oll o w- u p Call.C CI
Pr ot oc ol A me n d me nt [ADDRESS_663971] 2 0 1 8 Pa ge 3 3 of 6 0 
  
 T a ble 6- 2  Sc he d ule of Assess me nts:  P a rt 2 
 Scree ni n g C hec k-i n Tre at me nt C hec k- o ut F oll o w- u p 
E ve nts  D a ys - 2 9 
t o -2 D a y - 1 D a y 
1 D a y 
2 D a y 
3 D a y 
4  D a y 
5  D a y 
6  D a y 
7  D a y 
8 Cli nic 
Disc h ar g e  
or E T a 
D a y 9 S af et y F oll o w- u p 
C all ( a p pr o xi m atel y 
7 d a ys after Cli nic 
Disc h ar ge)  
I nf or me d C o nse nt X            
Assi g n me nt of Scree ni n g N u m ber X            
Re vie w of I ncl usi o n/ E xcl usi o n Criteria X X           
De m o gra p hic Data X            
Me dical Hist or y b X X           
Pri or Me dicati o ns X X           
Hei g ht, W ei g ht, B MI Calc ulati o n c X X           
Alc o h ol a n d Dr u g Scree n d X X           
Ser ol o g y T est ( H B c A b, H Bs A g, H C V 
A b, HI V)  X             
C o nfi ne me nt t o C R U  X X X X X X X X X X  
Assi g n me nt of S u bj ect N u m b er   X          
P h ysical E xa mi nati o n  e X X          X  
Cli nical La b orat or y E val uati o ns (cli nical c he mistr y T S H [ Scree ni n g o nl y], he mat ol o g y, uri nal ysis)
 f X  X     X     X  
Pr ot oc ol A me n d me nt [ADDRESS_663972] 2 0 1 8 Pa ge 3 4 of 6 0 
  
  Scree ni n g C hec k-i n Tre at me nt C hec k- o ut F oll o w- u p 
E ve nts  D a ys - 2 9 
t o -2 D a y - 1 D a y 
1 D a y 
2 D a y 
3 D a y 
4  D a y 
5  D a y 
6  D a y 
7  D a y 
8 Cli nic 
Disc h ar g e  
or E T a 
D a y 9 S af et y F oll o w- u p 
C all ( a p pr o xi m atel y 
7 d a ys after Cli nic 
Disc h ar ge)  
Vital Si g ns ( oral te m perat ure, B P, heart 
rate, a n d res pi[INVESTIGATOR_1305] y rate) g X  X  X  X X X X X X X X  
1 2-lea d E C G h X X X         X  
Oral L O X O- 2 9 2 1 6 0 m g A d mi nistrati o n 
i  
 X          
I V [1 4C]- L O X O- 2 9 2, < 1 0 0 μ g 
( ~ 1 μ Ci) A d mi nistrati o n i   X          
A E, S A E, a n d C o nc o mita nt 
Me dicati o ns a n d Pr oce d ures 
M o nit ori n g a n d Rec or di n g m        X-------------------------------------------------------------- O n g oi n g------------------------------------------------------ X 
A E = a d verse e ve nt; B MI = b o d y mass i n de x; B P = bl o o d press ur e; C R U = Cli nical Rese arc h U nit; E C G = electr ocar di o gra m; E T = ear l y ter mi nati o n; 
H B c A b = he p atitis B c ore a nti b o d y; H Bs A g = he p atitis B s urface a n ti ge n; H C V A b = he p atitis C vir us a nti b o d y; HI V = h u ma n i m m u n odeficie nc y vir us; I V = i ntra ve n o us; S A E = seri o us a d verse e ve nt; T S H = t h yr oi d-sti m ulati n g h or m o ne. C CI
Pr ot oc ol A me n d me nt [ADDRESS_663973] u g uri ne scree n ( w hic h i ncl u des c oti ni ne) will be c o n d ucte d at Scree ni n g a n d at C hec k-i n ( Da y - 1). A n alc o h ol breat h test will be c o n d ucte d at C hec k-i n 
o nl y. 
e A c o m plete p h ysical e xa mi nati o n will be c o n d ucte d at Scr ee ni n g a nd at Cli nic Disc har ge/ E T. A n a b bre viate d p h ysical e xa mi nati o n  ( ge neral, heart, l u n gs, 
a b d o me n, a n d s ki n) will be c o n d ucte d at C hec k-i n. 
f E ver y atte m pt will be ma de t o e ns ure bl o o d sa m ples f or t he cli nical c he mistr y pa nel are c ollecte d f oll o wi n g a fast fr o m f o o d f or at least [ADDRESS_663974] e d at Scree ni n g, C hec k-i n, o n Da y 4, a n d at Cli nic Disc har ge/ E T. 
g S u bj ects are t o re mai n s u pi [INVESTIGATOR_050] f or at least 5 mi n utes pri or t o vital si g ns meas ure me nts. Vital si g ns will be o btai ne d at S cree ni n g; C hec k-i n; o n Da y [ADDRESS_663975] d ose relati ve t o oral d ose a d mi nistrati o n; a n d dail y ( 2 4- h o ur i nter vals) u p t o a n d i ncl u di n g da y of Cli nic Disc har g e/ E T. W he n sc he d ule d at t he sa me 
n o mi nal ti mes, p ost d ose vital si g ns meas ure me nts are t o  be perf or me d pri or t o p ost d ose P K bl o o d dra ws (see Secti o n 6. 5 ), wit h bl o o d dra ws occ urri n g as cl ose 
t o t he n o mi nal ti mes as p ossi ble. 
h S u bj ects are t o re mai n s u pi [INVESTIGATOR_050] f or at least [ADDRESS_663976] d ose relati ve t o oral d ose a d mi ni strati o n, a n d at Cli nic Disc har ge/ E T. W he n sc he d ule d at t he sa me n o mi nal ti mes, p ost d ose E C Gs are t o be perf or me d pri or t o p ost d ose vital si g ns meas ure me nts a n d P K bl o o d dra ws (see Secti o n 6. 5 ), wit h bl o o d dra ws occ urri n g as cl ose t o t he n o mi nal ti mes as 
p ossi ble. 
i See Secti o n 4. [ADDRESS_663977] u d y fr o m t he ti me of si g n i n g t he i nf or me d c o nse nt,   
as descri be d i n Secti o n 6. 5. 1 , A p pe n di x C , a n d Secti o n 6. 3. 2 . A “ H o w D o Y o u Feel? ” A E i n q uir y will be perf or me d at Scree ni n g, C hec k -i n, eac h vital si g ns meas ure me nt, a n d d uri n g t he Safet y F oll o w- u p Call. 
 C CI
Pr ot oc ol A me n d me nt [ADDRESS_663978] u g S u p plies a n d Acc o u nt a bilit y 
T he S p o ns or ( or desi g nee) will pr o vi de t he I n v esti gat or ( or desi g nee) wit h a de q uate q u a ntities of 
t he st u d y dr u gs f or Part 1 (Ta ble 6- 3 ) a n d Part 2 ( Ta ble 6- 4 ). F or Part 1, n o nra di ola bel e d L O X O- 2 9 2 ( pr o vi de d as a p o w der) a n d [
1 4C]- L O X O- 2 9 2 ( pr o vi d e d as a s oli d) will be 
f or m ulate d b y C o va nce t o t he desire d c o n ce ntrati o n i n or der t o ac hi e ve t he fi nal oral d ose s ol uti o n ( ~ 4 0 μ Ci/ [ADDRESS_663979]). F or t he oral d os e p orti o n of Part 2, n o nra di ola bele d 
L O X O- 2 9 2 will be s u p plie d b y t he S p o ns or as 2 x 8 0- m g ca ps ules. F or t he I V d ose p orti o n of 
Part 2, [
1 4C]- L O X O- 2 9 2 ( pr o vi de d as a s oli d) will be f or m ulate d b y C o va n ce i n or der t o ac hie v e 
t he fi nal I V d ose s ol uti o n ( ~ 1 μ Ci/ < [ADDRESS_663980]). 
 
T a ble 6- [ADDRESS_663981] u gs:  P a rt [ADDRESS_663982] u g [1 4C]- L O X O- 2 9 2 L O X O- 2 9 2 
F or ma S oli d P o w der 
Stre n gt h N/ A N/ A 
S pecific Acti vit y ~ 1 0 0 μ Ci/ m g  N/ A 
S u p plier L o x o O nc ol o g y, I nc. L o x o O nc ol o g y, I nc. 
M a n uf act urer Selcia, Lt d. A vista P har ma S ol uti o ns, I nc. 
aS pecific i n gre die nts/ p urit y will be i d e ntifie d i n t h e Certificate of A nal ysis ( or e q ui vale nt) t h at is s u p plie d wit h t he st u d y d r u g(s). 
 
T a ble 6- [ADDRESS_663983] u gs:  P a rt [ADDRESS_663984] u g L O X O- 2 9 2 [1 4C]- L O X O- 2 9 2  
F or ma Oral Ca ps ule S oli d 
Stre n gt h 8 0 m g N/ A 
S pecific Acti vit y N/ A ~ 1 0 0 μ Ci/ m g  
S u p plier L o x o O nc ol o g y, I nc. L o x o O nc ol o g y, I nc. 
M a n uf act urer A vista P har ma S ol uti o ns, I nc. Selcia, Lt d. 
aS pecific i n gre die nts/ p urit y will be i d e ntifie d i n t h e Certificate of A nal ysis ( or e q ui vale nt) t h at is s u p plie d wit h t he st u d y d r u g(s). 
 
T he l ot n u m bers ( or e q ui vale nt) f or t he st u d y dr u gs will be pr o vi de d t o t he C R U b y t he 
s u p plier/ ma n ufact ur er w he n s u p plies are s hi p pe d. 
N o nra di ola bele d st u d y dr u g ca ps ules will be st ore d at r o o m te m perat ur e ( bet wee n 1 5 C a n d 
3 0 C) u n der sec ure c o n diti o ns. N o nra di ola bele d  st u d y dr u g p o w der will be st ore d at r o o m 
te m perat ur e ( bet w ee n 1 5 C a n d 3 0 C) u n der sec ure c o n diti o ns. Ra di ola bel e d st u d y dr u g will be 
st ore d fr oze n as i n dicat e d o n t he pr o d uct la bel a nd/ or Certificate of A nal ysis ( or e q ui vale nt).  
Pr ot oc ol A me n d me nt [ADDRESS_663985] 2 0 1 8 Pa ge 3 7 of 6 0 
 T he I n vesti gat or ( or desi g nee) will mai ntai n a n acc urate rec or d of t he recei pt of t he cli nical trial 
materials as s hi p pe d b y t he S p o ns or ( or desi g nee), i ncl u di n g t he dat e recei v e d. O ne c o p y of t his recei pt will be ret ur ne d t o t he S p o ns or w he n t he c o nte nts of t he s hi p me nt ha ve bee n verifi e d. I n a d diti o n, a n acc urate dr u g dis p ositi o n rec or d will be ke pt, s pecif yi n g t he a m o u nt dis pe nse d t o eac h s u bject a n d t he dat e of dis pe nsati o n. T his dr u g acc o u nta bilit y rec or d will be a vaila ble f or i ns pecti o n at a n y ti me. At t he c o m pleti o n of t he st u d y, t he ori gi nal dr u g acc o u nta bilit y rec or d will be a vaila ble f or re vi e w b y t he S p o ns or o n re q uest. 
At t he c o m pleti o n of t he st u d y, all u n use d dr u g s u p plies will be ret ur ne d t o t he S p o ns or ( or 
desi g nee) or dis p os e d of b y t he C R U per t he S p o ns or’s ( or desi g n ee’s) writte n i nstr ucti o ns.  
6. 2. [ADDRESS_663986] a w n b y t he I n vesti gat or ( or desi g nee) or w h o v ol u ntaril y wit h dra w pre mat urel y fr o m t he st u d y, re pla ce me nt s u bjects will be e nr olle d o nl y if dee m e d necessar y b y t he S p o ns or. Re place me nt s u bjects will be assi g ne d a s u bject n u m ber b y a d di n g [ADDRESS_663987] t he y are re placi n g (e g, S u bject N o. [ADDRESS_663988] N o. 0 0 5). 
6. 2. [ADDRESS_663989]’s act ual d ose ti me will be rec or de d i n t he s o urce d oc u me nts a n d tra nscri be d i nt o t he e C R Fs. 
Eac h oral d ose will be a d mi nist ere d orall y w it h a p pr o xi matel y [ADDRESS_663990] (i e, at least 8 h o urs) fr o m f o o d ( n ot i ncl u di n g 
Pr ot oc ol A me n d me nt [ADDRESS_663991] 2 0 1 8 Pa ge 3 8 of 6 0 
 water) a n d will be f oll o w e d b y a fast fr o m f o o d ( n ot i ncl u di n g water) f or at least [ADDRESS_663992] d ose; at all ot her ti mes d uri n g t he st u d y, s u bjects ma y c o ns u me water a d li bit u m. 
E x ce pt w he n t he y are usi n g t he t oilet, st u d y s u bj ects will be o bser ve d f or a p pr o xi matel y [ADDRESS_663993] d ose. S u bjects will n ot la y s u pi [INVESTIGATOR_050] f or 1 h o ur f oll o wi n g eac h d ose a d mi nistere d, e x ce pt as necessitate d b y t he o cc urre nce of a n A E(s) a n d/ or st u d y pr oce d ures. 
6. 2. [ADDRESS_663994] u d y Restricti o ns 
6. 3. 1  Diet, Fl ui d, a n d Acti vit y C o ntr ol 
S u bjects are re q uire d t o r efrai n fr o m use of t o bacc o- or nic oti ne-c o nt ai ni n g pr o d ucts wit hi n 
3 m o nt hs pri or t o C hec k-i n u ntil Cli nic Disc har ge. 
F o o ds a n d be v era ges c o ntai ni n g p o p p y see ds, gra p efr uit, or Se ville ora n ges will n ot be all o we d 
fr o m 7 da ys pri or t o C hec k-i n u ntil Cli nic Disc har ge. 
S u bjects are re q uire d t o a bstai n fr o m c o ns u mi n g alc o h ol-, caffei ne-, or xa nt hi ne-c o ntai ni n g 
f o o ds a n d be vera ges fr o m 7 2 h o urs pri or t o C heck-i n u ntil Cli nic Disc har ge, u nl ess dee me d acce pta ble b y t he I n v esti gat or ( or desi g n ee). 
S u bjects will refrai n fr o m stre n u o us e x ercise fr o m [ADDRESS_663995] u d y (ie, will n ot be gi n a ne w e x ercise pr o gra m or partici p ate i n a n y u n us u all y str e n u o us p h ysical e x erti o n). 
W hile c o nfi ne d at t he C R U, s u bjects will recei v e  a sta n dar dize d hi g h-fi ber diet at sc he d ule d 
ti mes t hat d o n ot c o nflict wit h ot her st u d y-related acti vities. Pi[INVESTIGATOR_23185] d pr u nes or pr u ne j uice m a y be 
gi ve n o n a n as- n ee de d b asis t o ai d i n n or mal b o wel f u ncti o n a n d will n ot be c o nsi dere d a 
c o nc o mita nt me dicati o n.  
Pr ot oc ol A me n d me nt [ADDRESS_663996] u g occ urre d wit hi n 3 0 da ys or 5 half-li ves (if k n o w n), w hic h e ver is l o n ger, pri or t o C hec k-i n u ntil Cli nic Disc har ge. 
S u bjects will refrai n fr o m t he use of a n y me dicati o ns/ pr o d ucts k n o w n t o alter dr u g A M E 
pr ocesses, i n partic ular str o n g i n d u cers or i n hi bit ors of C Y P [ADDRESS_663997]. J o h n’s w ort, wit hi n 3 0 da ys pri or t o C hec k-i n, u nless de e me d acce pta bl e b y t he I n vesti gat or ( or desi g n ee). 
S u bjects will als o refrai n fr o m t he use of a n y pres cri pti o n me dicati o ns/ pr o d ucts d uri n g t he 
i nter val fr o m 1 4 da ys pri or t o C hec k-i n t hr o u g h Cli nic Disc har ge, u nless d ee me d acce pta ble b y 
t he I n v esti gat or ( or d esi g nee). I n a d diti o n, s u bjects will refrai n fr o m t he use of a n y o ver-t he- c o u nter n o n pres cri pti o n me dicati o ns  (i ncl u di n g vita mi ns, mi nerals, a n d p h yt ot hera pe utic/ her bal/ pla nt- deri ve d pre parati o ns) fr o m 7 da ys pri or t o C hec k-i n t hr o u g h Cli nic Disc har ge, u nl ess dee me d acce pta ble b y t he I n v esti gat or ( or desi g nee). 
Pi[INVESTIGATOR_23185] d pr u nes or pr u ne j ui ce ma y be us e d t o h el p wit h b o wel m o ve me nts if necessar y. U p t o 
[ADDRESS_663998] ere d if a p pr o ve d b y t he I n v esti gat or ( or desi g nee). T h e a d mi nistrati o n of a n y ot her c o nc o mita nt me dicati o ns d uri n g t he st u d y is pr o hi bite d wit h o ut pri or a p pr o val of t he I n vesti gat or ( or desi g nee), u nless its use is dee me d necessar y i n a me dic al e mer ge nc y. A n y m e dicati o n ta ke n b y a s u bject d uri n g t he st u d y a n d t he 
reas o n f or its use will be d oc u me nte d i n t he s o urce d oc u me nts a n d t he e C R F.  
6. 3. [ADDRESS_663999] u g a d mi nistrati o n: 
 Male steriliz ati o n, wit h d oc u me nte d c o nfir mati o n of s ur gical s uc cess. Male s u bjects will 
be s ur gicall y sterile f or at least [ADDRESS_664000] f oll o w t he c o ntrace pti o n met h o ds bel o w: 
o  Male c o n d o m wit h s per mici de, a n d 
o  F or fe male part ner of m ale st u d y partici pa nt: 
 i ntra uteri ne de vic e (I U D; h or m o nal I U D; e g, Mir e na
®). C o p per I U Ds are 
acce pta ble (e g, Para Gar d®); 
 esta blis he d use of oral, i m pla nte d, tra ns der mal, or h or m o nal met h o d of 
c o ntrace pti o n ass ociate d wit h  i n hi biti o n of o v ulati o n; 
 bilateral t u bal li gati o n; or 
Pr ot oc ol A me n d me nt [ADDRESS_664001] 2 0 1 8 Pa ge 4 0 of 6 0 
  s p o n ge, cer vi cal c a p, or dia p hra g m ( barrier m et h o d). 
S u bjects w h o practice tr u e a bsti ne nce b eca use of t he s u bject’s lifest yle c h oi ce (ie, t he s u bj ect 
s h o ul d n ot bec o me a bsti ne nt j ust f or t he p ur p ose of st u d y partici pati o n) are e x e m pt fr o m c o ntrace pti ve re q uir e me nts. Peri o dic a bsti ne nce (e g, cale n dar, o v ulati o n, s y m pt ot her mal, p ost o v ulati o n met h o ds f or t he fe mal e part ner of a male s u bject) a n d wit h dra wal are n ot acce pta ble met h o ds of c o ntrace pti o n. If a s u bject w h o is a bsti ne nt at t he ti me of si g ni n g t he I C F bec o mes se x uall y acti ve, t he y m ust a gree t o use c o ntrace pti o n as d escri be d a b o ve.  
F or male s u bjects, se x ual i nterc o urse wit h f e male  part ners w h o are pre g n a nt or breastf ee di n g 
s h o ul d be a v oi de d u nless c o n d o ms wit h s per mici de are us e d fr o m t he ti me of t he first d ose u ntil 
[ADDRESS_664002] y. 
6. 4  P h ar m a c o ki netic, [
1 4C] R a di o acti vit y, a n d Met a b olite Pr o ce d ures 
6. 4. 1  P h ar m a c o ki netic, [1 4C] R a di o acti vit y, a n d Met a b olite Bl o o d S a m ple C ollecti o n 
Part 1: 
Bl o o d sa m ples f or L O X O- 2 9 2 a nal ysis, t otal ra di oacti vit y, a n d m eta b olite 
pr ofili n g/c h aracteriz ati o n will be c ollecte d v ia direct ve ni p u nct ure. Bl o o d sa m ples will be 
c ollecte d at t he ti me p oi nts s pecifie d i n Ta ble 6- 1 . 
Part 2: 
Bl o o d sa m ples f or d eter mi na ti o n of L O X O- 2 9 2 a n d [1 4C]- L O X O- [ADDRESS_664003] or a ge, a n d s hi p pi n g i nstr ucti o ns f or t hese bl o o d sa m ples will be prese nt e d i n a 
se parat e d oc u me nt. 
6. 4. 2  P h ar m a c o ki netic, [
1 4C] R a di o acti vit y, a n d Met a b ol ite Uri ne S a m ple C ollecti o n 
Part 1: 
Uri ne sa m ples f or t otal ra di oacti vit y c o n ce ntrat i o ns a n d meta b olite pr ofili n g/c h aracteriz ati o n will be c ollecte d at t he ti me i nter vals s pecifi e d i n Ta bl e 6- [ADDRESS_664004] 2 0 1 8 Pa ge 4 1 of 6 0 
 Part 2: 
Uri ne sa m ples f or deter mi nati o n of L O X O- 2 9 2, [1 4C]- L O X O- [ADDRESS_664005] or a ge, a n d s hi p pi n g i nstr ucti o ns f or  t hese uri ne sa m ples will be prese nt e d i n a 
se parat e d oc u me nt. 
6. 4. 3   [1 4C] R a di o acti vit y a n d Met a b olite Fec al S a m ple C ollecti o n 
Part 1: 
Fecal sa m ples f or t otal r a di oacti vit y c o n ce ntrat i o ns a n d meta b olite pr ofili n g/c h aracteriz ati o n will 
be c ollecte d at t he ti me i nter vals s pecifi e d i n Ta bl e 6- [ADDRESS_664006] pri or t o d ose a d mi nistrati o n o n Da y 1. 
Part 2: 
Fecal sa m ples f or d eter mi nati o n of t o tal ra di oacti vit y c o nce ntrati o ns will be c ollecte d at t he ti me i nter vals s pecifie d i n T a ble 6- 2. If p ossi ble, a si n gl e baseli ne fecal sa m ple will be c ollecte d fr o m after C hec k-i n o n Da y - [ADDRESS_664007]’s s o urce d oc u me nts a n d e C R F. V o mit us will be a nal yze d as dee m e d a p pr o priat e. 
6. 4. 5  A n al ytic al Met h o d ol o g y 
I n Part 1, c o nce ntrati o ns of t otal ra di oacti vit y will be deter mi ne d i n w h ole bl o o d, plas ma, uri ne, 
a n d feces usi n g li q ui d sci ntillati o n c o u nti n g ( L S C).  Plas ma c o nce ntr ati o ns of L O X O- 2 9 2 will be 
deter mi ne d usi n g a vali d ate d bi oa nal ytical met h o d. Pr ofili n g a n d c h aracteriz ati o n of meta b olites 
i n plas ma, uri ne, a n d feces will be co n d ucte d usi n g sta n dar d la b orat or y pr oce d ures.  
I n Part 2, c o nce ntrati o ns of t otal ra di oacti vit y i n uri ne a n d feces will be d eter mi ne d usi n g A M S 
a n d/ or L S C. Plas ma a n d uri ne c o nce ntrati o ns of [
1 4C]- L O X O- [ADDRESS_664008] 2 0 1 8 Pa ge 4 2 of 6 0 
 S pecifics of t he a n al yti cal met h o ds will be pr o vi de d i n a se parate d oc u me nt.  
6. 5  S afet y Pr oce d ures 
Safet y e val uati o ns ma y b e re peate d at t he I n vesti gat or’s  ( or d esi g n ee’s) discreti o n. 
 E ver y eff ort will be ma d e t o sc he d ule a n d p e rf or m t he pr oce d ures i n acc or da nce wit h t he n o mi nal ti me, gi vi n g c o nsi derati o ns t o a p pr o pri ate p ost ure c o n diti o ns, practical restricti o ns, a n d t he ot her pr oce d ures t o b e perf or me d at t he s a me ti me p oi nt. E x ce pt f or at Scree ni n g a n d C hec k-i n, t he or der of pri orit y f or s c he d uli n g pr oce d ures ar o u n d a ti me p oi nt is (i n desce n di n g or der of pri orit y): 
 D osi n g 
 P ost d ose P K bl o o d sa m pli n g ( w hic h i ncl u d es L O X O- 2 9 2, [
1 4C]- L O X O- 2 9 2 [ Part 2 o nl y], 
a n d t otal ra di oacti vit y c o nce ntrati o ns, a n d met a b olite pr ofili n g/c haract erizati o n [ Part 1 
o nl y]) 
 Start a n d e n d of uri ne a n d fecal c ollecti o ns (f or dr u g ass a y) 
 Vital si g ns meas ur e me nts 
 E C Gs  Bl o o d a n d uri ne s a m ples f or cli nical la b orat ories  P h ysical e x a mi nati o ns. 
6. 5. 1  A d verse E ve nts 
A d verse e ve nt defi niti o ns; assi g n me nt of se v e rit y, ca usalit y, acti o n ta ke n, a n d o utc o me; a n d 
pr oce d ures f or re p orti n g seri o us A Es ( S A Es) are d etaile d i n A p pe n di x C . 
T he c o n diti o n of eac h s u bject will be m o nit ore d fr o m ti me of si g ni n g t h e I C F t o Cli nic 
Disc har ge. I n a d diti o n, s u bjects will be o bser ve d f or a n y si g ns or s y m pt o ms a n d as ke d a b o ut t heir c o n diti o n b y o pe n q uesti o ni n g, s uc h as “ H o w d o y o u feel? ” or “ H o w h a ve y o u bee n feeli n g si nce y o u were last as ke d ? ”, as s pecifie d i n Ta ble 6- [ADDRESS_664009]’s res p o ns es t o H o w D o Y o u Feel ? 
i n q uiries, or n ote d o n la b orat or y tests, vit al si g ns meas ure me nts, E C Gs, or p h ysical e x a mi nati o ns, will be rec or de d t hr o u g h o ut t he st u d y (ie, fr o m si g ni n g of t he I C F u ntil St u d y C o m pleti o n), eit her as s u bject me dical hist or y (if t he e ve nt is n o nseri o us a n d re p orte d pri or t o d osi n g) or as A Es (if s eri o us or t he e ve nt oc c urs  after a d mi nistrati o n of L O X O- 2 9 2). T h e nat ure, ti me of o nset, d urati o n, a n d se verit y will be d oc u me nte d, t o get her wit h a n I n v esti gat or’s ( or 
Pr ot oc ol A me n d me nt [ADDRESS_664010] 2 0 1 8 Pa ge 4 3 of 6 0 
 desi g nee’s) o pi [INVESTIGATOR_9384] o n of t h e  relati o ns hi p t o st u d y dr u g. A d v erse e ve nts rec or de d d uri n g t he c o urs e 
of t he st u d y will be f oll o we d u p, w here p ossi ble, u ntil t he y ha ve res ol ve d or bec o me sta bl e. T his will be c o m plete d at t he I n vesti gat or’s ( or desi g n ee’s) discreti o n.  
S u bjects will recei ve a Safet y F oll o w- u p Call a p pr o xi matel y [ADDRESS_664011] ma y be re q uir e d t o re mai n at t he C R U f or l o n ger at t he discreti o n of t he 
I n v esti gat or ( or desi g n ee). 
Si nce t he safet y pr ofile of L O X O- 2 9 2 i n h u ma ns has n ot bee n f ull y esta blis he d, all S A Es relate d 
t o L O X O- 2 9 2 will be c o nsi dere d u ne x pecte d a n d re p orte d as s us pecte d u n e x pecte d seri o us 
a d verse reacti o ns. 
6. 5. 2  Cli nic al L a b or at or y E v al u ati o ns 
Cli nical la b orat or y e val u ati o ns (i ncl u di n g cli nical c he mistr y p a nel [s h o ul d be faste d at least 
8 h o urs], t h yr oi d-sti m ulati n g h or m o ne [ Scree ni n g o nl y], he m at ol o g y, a n d uri nal ysis; A p pe n di x A ) will be c ollecte d at t he ti me p oi nts s pecifie d i n Ta ble 6- [ADDRESS_664012] u gs of a b use, i ncl u di n g c oti ni ne ( n ot i n cl u di n g al c o h ol), will be perf or me d at Scree ni n g a n d re peate d (i ncl u di n g al c o h ol) at C hec k-i n.  
6. 5. 3   Vit al Si g ns 
Vital si g ns meas ur e me nts (i ncl u di n g oral te m perat ure, B P, heart rat e, a n d res pi[INVESTIGATOR_1305] y rate) will 
be o btai ne d at t he ti me p oi nts s pecifie d i n Ta ble 6- [ADDRESS_664013] 5 mi n utes pri or t o o btai ni n g a n E C G meas ure m e nt. 
T he E C G para meters (i n cl u di n g heart rate; P R, Q R S, a n d Q T i nter vals; a n d Q Tc F) a n d t he 
I n v esti gat or’s ( or desi g nee’s) o verall i nter pretati o n of t he E C G will be rec or de d i n t he e C R F. 
Pr ot oc ol A me n d me nt [ADDRESS_664014] 2 0 1 8 Pa ge 4 4 of 6 0 
 6. 5. 5   P h ysic al E x a mi n ati o ns 
C o m plete p h ysical e x a mi nati o ns a n d a b bre vi ate d p h ysical e x a mi nati o n ( ge neral, he art, l u n gs, 
a b d o me n, a n d s ki n) will be perf or me d at t he ti me p oi nts s pecifie d i n Ta ble 6- [ADDRESS_664015] u d y (si g ne d 
i nf or me d c o nse nt). 
7. 3  P h ar m a c o ki netic A n al ysis 
Part 1: 
W he ne ver p ossi ble, t he f oll o wi n g P K para meters will be calc ulate d f or eac h s u bject, base d o n 
t he plas ma c o nce ntrati o ns of L O X O- [ADDRESS_664016] q ua ntifia ble c o nce ntr ati o n, 
calc ulate d usi n g t he li ne ar tra pez oi dal r ule f or i ncreasi n g 
c o nce ntr ati o ns a n d t he l o garit h mic r ule f or decreasi n g c o nce ntr ati o ns 
A U C
0-    A U C e xtra p olate d t o i nfi nit y, cal c ulate d usi n g t he f or m ula: 
A U C 0- = A U C last + ( C last ÷ z)  
Pr ot oc ol A me n d me nt [ADDRESS_664017] q ua ntifia ble c o nce ntr ati o n a n d z is t he 
a p pare nt ter mi nal eli mi nati o n rate c o nsta nt 
z   a p pare nt ter mi nal eli mi nati o n rate c o nsta nt,  
   w here  Z is t he ma g nit u d e of t he sl o pe of t he li ne ar re gressi o n of 
t he l o g c o n ce ntr ati o n vers us-ti me pr ofile d uri n g t he ter mi nal p hase 
t1/ 2   a p pare nt ter mi nal eli mi nati o n half-life ( w he ne v er p ossi ble),  
   w here  t 1/ 2 = nat ural l o g ( 2)/ z 
C L/ F   a p pare nt s yste mic cleara nce (f or L O X O- 2 9 2 o nl y) 
Vz/ F   a p pare nt v ol u me of distri b uti o n d uri n g t he ter mi nal p hase (f or 
L O X O- 2 9 2 o nl y) 
 
Bl o o d/ Plas ma A U C Rati o 
 A U C 0- ∞ of t otal ra di oacti vit y i n w h ole bl o o d/ A U C 0- ∞ of t otal 
ra di oacti vit y i n plas ma 
 
Plas ma L O X O- 2 9 2 / T otal Ra di oacti vit y A U C Rati o 
 A U C 0- ∞ of L O X O- 2 9 2 i n plas ma/ A U C 0- ∞ of t otal ra di oacti vit y i n 
plas ma. 
 
A d diti o nall y, bl o o d-t o- pl as ma rati os at e ac h sa m p li n g ti me p oi nt will be calc ulate d t o deter mi ne partiti o ni n g of t otal ra di o acti vit y i nt o re d bl o o d c ells.  
I n a d diti o n, f or eac h s u bj ect, t he f oll o wi n g P K para meters will be calc ulate d w he ne ver p ossi ble, 
base d o n t he uri ne c o nce ntrati o ns of t otal ra di oacti vit y: 
A
e u   a m o u nt e x crete d i n uri ne per sa m pli n g i nter val 
C u m A e u c u m ulati ve a m o u nt e x crete d i n uri ne  
%fe u   perce nt a ge of d os e e x cret e d i n uri ne per s a m pli n g i nter val, w here %f
e u = 1 0 0 ( A e u/ d ose) 
C u m %f e u  c u m ulati ve perce nta ge of d ose e x crete d i n uri ne. 
 
F or eac h s u bject, t he f oll o wi n g P K para meters will be calc ulate d w he ne v er p ossi ble, base d o n t he fecal c o nce ntrati o ns of t otal ra di oacti vit y: 
 A
ef a m o u nt e x crete d i n feces per sa m pli n g i nter val 
C u m A ef c u m ulati ve a m o u nt e x crete d i n feces 
 %f ef perce nt a ge of d os e e x cret e d i n feces per s a m pli n g i nter val, w here 
%fef = 1 0 0 ( A ef/ d ose) 
C u m %f ef  c u m ulati ve perce nta ge of d ose e x crete d i n feces. 
  
Pr ot oc ol A me n d me nt [ADDRESS_664018] 2 0 1 8 Pa ge 4 6 of 6 0 
 Part 2: 
Oral d ose P K:  W he ne ver p ossi ble, t he f oll o w i n g P K para meters will be calc ulate d f or eac h s u bject, base d o n t he plas ma c o nce ntr ati o ns of L O X O- 2 9 2: 
C
ma x ma xi m u m o bser ve d c o nce ntrati o n 
Tma x   ti me t o ma xi m u m o bser ve d c o nce ntrati o n 
A U C last A U C fr o m ti me [ADDRESS_664019] q ua ntifia ble c o nce ntr ati o n 
A U C 0-    A U C e xtra p olate d t o i nfi nit y, cal c ulate d as d escri be d a b o ve 
z   a p pare nt ter mi nal eli mi nati o n rate c o nsta nt 
t1/ 2   a p pare nt ter mi nal eli mi nati o n half-life ( w he ne v er p ossi ble),  
   w here  t 1/ 2 = nat ural l o g ( 2)/ Z 
F   a bs ol ute bi oa vaila bilit y, calc ulate d usi n g t he f or m ula: 
   F = A U C 0- ∞  ( oral) x D ose (I V) 
         A U C 0- ∞  (I V) x D ose ( oral) 
C L/ F    a p pare nt  s yste mic  cleara nce  V
z/ F   a p pare nt v ol u me of distri b uti o n d uri n g t he ter mi nal p hase. 
 I ntr a ve n o us d ose P K:  F or eac h s u bj ect, t he f oll o wi n g P K para meters will be calc ul ate d w he ne ver p ossi ble, base d o n t he plas ma c o nce ntrati o ns of [
1 4C]- L O X O- 2 9 2: 
Cma x ma xi m u m o bser ve d c o nce ntrati o n 
Tma x   ti me t o ma xi m u m o bser ve d c o nce ntrati o n 
A U C last A U C fr o m ti me [ADDRESS_664020] q ua ntifia ble c o nce ntr ati o n 
A U C 0-    A U C e xtra p olate d t o i nfi nit y, cal c ulate d as d escri be d a b o ve 
z   a p pare nt ter mi nal eli mi nati o n rate c o nsta nt 
t1/ 2   a p pare nt ter mi nal eli mi nati o n half-life ( w he ne v er p ossi ble),  
   w here  t 1/ 2 = nat ural l o g ( 2)/ Z 
C L    s yste mic  cl eara nce  V
z   v ol u me of distri b uti o n d uri n g t he ter mi nal p hase 
Vss   v ol u me of distri b uti o n at stea d y st ate. 
 I n a d diti o n, f or eac h s u bj ect, t he f oll o wi n g P K para meters will be calc ulate d w he ne ver p ossi ble, base d o n t he uri ne c o nce ntrati o ns of L O X O- 2 9 2, [
1 4C]- L O X O- 2 9 2, a n d t otal ra di oacti vit y: 
Ae u   a m o u nt e x crete d i n uri ne per sa m pli n g i nter val 
C u m A e u c u m ulati ve a m o u nt e x crete d i n uri ne 
C LR re nal cleara nce ( L O X O- 2 9 2 a n d [1 4C]- L O X O- 2 9 2 o nl y), w h ere 
C LR = A e u/ A U C  
 A U C 0- ∞ ma y b e use d, if a p pr o priate   
%fe u   perce nt a ge of d os e e x cret e d i n uri ne per s a m pli n g i nter val, w here %f
e u = 1 0 0 ( A e u/ d ose) 
Pr ot oc ol A me n d me nt [ADDRESS_664021] 2 0 1 8 Pa ge 4 7 of 6 0 
 C u m %f e u  c u m ulati ve perce nta ge of d ose e x crete d i n uri ne. 
 
W he ne ver p ossi ble, t he f oll o wi n g P K para meters will be calc ulate d f or eac h s u bject, base d o n t he fecal c o nce ntrati o ns of t otal ra di oacti vit y:  A
ef a m o u nt e x crete d i n t he feces per s a m pli n g i nter val 
C u m A ef c u m ulati ve a m o u nt e x crete d i n feces 
 %f ef perce nt a ge of d os e e x cret e d i n feces per s a m pli n g i nter val, w here %f
ef = 1 0 0 ( A ef/ d ose) 
C u m %f ef  c u m ulati ve perce nta ge of d ose e x crete d i n feces. 
 P har mac o ki netic calc ulati o ns will be perf or me d, if a p pr o priate, us i n g c o m m ercial s oft w are s u c h 
as P h oe ni x
™ Wi n N o nli n® Versi o n 6. 4 or hi g h er ( Certara U S A I nc.). 
P har mac o ki netic para met ers f or rele va nt met a b olites of L O X O- 2 9 2 m a y be calc ulate d i n Part 1 
a n d/ or Part 2, as dee me d a p pr o priate, b ase d o n plas ma, uri ne, a n d/ or fecal c o nce ntrati o n le vels.  
Ot her para meters m a y be a d de d as a p pr o priate. Fi na l P K para meters re p orte d will be detaile d i n 
t he Statistical A nal ysis Pla n ( S A P). 
P har mac o ki netic a n al ysis will use act ual ti mes  as r ec or de d o n t h e e C R F. Ot her data h a n dli n g 
pr oce d ures will be detail e d i n t he S A P. 
7. [ADDRESS_664022] atistic al A n al ysis of P h ar m a c o ki netic D at a 
F or Parts 1 a n d 2, d escri pti ve statistics ( n u m ber of o bser vati o ns, arit h metic mea n, sta n dar d 
de viati o n, me dia n, mi ni m u m, ma xi m u m, ge o metric m ea n, a n d ge o metric c oeffi cie nt of variati o n) will be calc ulate d f or t he P K para meters. N o  f or m al statistical a nal ys es are pla n ne d. 
S pecificati o n of P K para meters f or a nal ysis; pr oce d ures f or acc o u nti n g f or missi n g, u n us e d, or 
s p uri o us data; pr oce d ures f or re p orti n g d e viati o ns fr o m t he ori gi nal statistical pla n; a n d selecti o n of s u bjects t o be i ncl u de d i n t he a nal ys es p o p ulati o n(s), as a p plica ble, will be prese nt e d i n t he Cli nical St u d y Re p ort a n d/ or S A P as a p pr o priate. 
7. [ADDRESS_664023] atistic al A n al yses of S afet y D at a 
F or Parts 1 a n d 2, d escri pti ve statistics will be calc ulate d o n t he safet y p ara meters. N o f or m al 
statistical a nal ys es are pla n ne d. 
All A Es will be c o de d b y t he Me dical Dicti o na r y f or Re g ul at or y Acti vities ( Versi o n 2 0. 0 or 
hi g her). Eac h si g n or s y m pt o m re p orte d will be gra de d o n t he Nati o nal I nstit uti o n of Healt h’s 
Pr ot oc ol A me n d me nt [ADDRESS_664024] 2 0 1 8 Pa ge 4 8 of 6 0 
 C o m m o n Ter mi n ol o g y Criteria f or A d vers e E ve nts Versi o n 5. 0 ( or hi g her) t o xicit y gra di n g scale 
as refere n ce d i n  A p p e n di x C . T he n u m ber ( %) of s u bjects wit h a n y A E will be s u m mariz e d b y 
s yste m or ga n class a n d preferre d t er m. Des cri pti ve statistics will be pr o vi de d f or cli nic al la b orat or y val u es, vital si g ns, a n d E C Gs. C o nc o mita nt me dicati o ns will be liste d a n d c o de d acc or di n g t o t he W orl d Healt h Or ga niz ati o n Dr u g Dicti o nar y ( Se pte m ber 2 0 1 5 or later). A d diti o nal details will be pr o vi de d i n t he S A P. 
7. [ADDRESS_664025] data (e g, wr o n g d ata ri g ht dat a ). If t he reas o n f or t he c ha n ge is n ot a p pare nt, 
a brief e x pla nati o n f or t he c ha n ge will be writ te n a djace nt t o t he c h a n ge b y t he cli nicia n. 
T he Data M a na ge m e nt Pla n will be a p pr o ve d b y t he S p o ns or. Data will be vali date d d uri n g dat a e ntr y b y t he C R U a n d verifi e d b y t he St u d y M o nit or. Dat a will 
t he n be re vie we d b y t he data ma na ge me nt gr o u p t o res ol ve a n y o utsta n di n g iss ues. Listi n gs will be ge nerate d after t he d at a base is clea ne d b y  D ata Ma na ge me nt a n d will be re vie we d b y t h e C o va nce scie ntific t ea m. T he e C R F a n d a ncillar y da ta will be c o n verte d i nt o fi nal S A S datasets f oll o wi n g St u d y Data Ta b ulati o n M o del or clie nt-pr o vi de d s pecificati o ns. T he fi nal datas ets 
str uct ure will be verifie d usi n g We b S u b missi o n Data Ma na ger
®, w hile t he dataset c o nte nt will 
be peer re vie we d b y a n i n de pe n de nt pr o gra m mer. 
T he ta bles, fi g ures, a n d listi n gs ( T F Ls) will be  pr o gra m me d per t h e fi nal S A P. All T F Ls will be 
peer re vie we d b y a n i n de pe n de nt pr o gra m mer. I n a d diti o n, draft T F Ls will be re vie we d b y t he C o va nce scie ntific t ea m d uri n g t he dr y r u n a n d d ata re vie w me eti n gs. 
T he peer re vie w will be perf or me d b y i n d e pe n de nt pr o gra m mers f oll o wi n g t he q u alit y c o ntr ol 
pr ocess a n d pr o gra m mi n g c h ec klists. 
7. [ADDRESS_664026] 2 0 1 8 Pa ge 4 9 of 6 0 
 8  A D MI NI S T R A TI V E A S P E C T S 
8. 1  C h a n ge i n Pr ot oc ol 
T here will be n o alterati o ns i n t he pr ot oc ol  wit h o ut a gree me nt b et wee n t h e S p o ns or a n d t he 
I n v esti gat or ( or d esi g n ee). 
T here will be n o alterati o ns i n t he pr ot oc ol affecti n g s u bject s afet y wit h o ut t he e x press writte n 
a p pr o val of t he S p o ns or, I n v esti gat or ( or d esi g n ee), a n d t he I R B (see F or m F D A 1 5 7 2). 
8. 2  Site I niti ati o n Visit/I n vesti g at or Meeti n g 
Pri or t o t he start of t he cli nical st u d y, t he re pres e ntati ve(s) of t he S p o ns or will meet wit h t he 
I n v esti gat or ( or d esi g n ee) a n d a p pr o priate cli nical staff t o fa miliarize t he I n vesti gat or ( or desi g nee) a n d cli nical staff wit h t he materials n ecessar y f or c o n d ucti n g t he cli nical st u d y. 
8. [ADDRESS_664027] u d y, as well as all i nf or mati o n c ollecte d/ d oc u me nte d 
d uri n g t he st u d y, will be re gar de d as c o nfi de nti al. T he I n vesti gat or ( or desi g nee) a grees n ot t o discl ose s uc h i nf or mati o n i n a n y w a y wit h o ut pri or writte n per missi o n fr o m t he S p o ns or. 
A n y p u blicati o n of t he res ults, i n part or i n t o tal ( e g, articles i n j o ur nals or n e ws pa pers, oral 
prese ntati o ns, a bstracts) b y t he I n vesti gat or ( or d esi g nee) or t heir re prese nt ati ve(s), s hall re q uire 
pri or n otificati o n a n d re vie w, wit hi n a reas o n a ble ti mefra me, b y t he S p o ns or, a n d ca n n ot b e ma de i n vi olati o n of t he S p o ns or’s c o nfi de ntialit y restricti o ns or t o t he detri me nt of t he S p o ns or’s i ntellect ual pr o pert y ri g hts.  
8. 4  M o nit ori n g 
T he S p o ns or will desi g nate a S p o ns or’s St u d y M o nit or w h o will be res p o nsi ble f or m o nit ori n g 
t his cli nical trial. T he S p o ns or’s St u d y M o nit or will m o nit or t he st u d y c o n d uct, pr o per e C R F a n d s o urce d oc u m e ntati o n c o m pleti o n an d rete nti o n, a n d acc urate st u d y dr u g acc o u nta bilit y. T o t his e n d, t he S p o ns or’s St u d y M o nit or will visit t he C R U at s uita ble i nter vals a n d be i n fre q u e nt 
c o ntact t hr o u g h ve r bal a n d writte n c o m m u nicati o n. It is esse ntial t hat t he S p o ns or’s St u d y 
M o nit or has access t o all d oc u me nts (relat e d t o t he st u d y a n d t he i n di vi d ual partici pa nts) at a n y ti me t hese are re q ueste d. I n t ur n, t h e S p o ns or’s St u d y M o nit or will a d here t o all re quire me nts f or s u bject c o nfi de ntialit y as o utli ne d i n t he I C F. T h e I n v esti gat or ( or d esi g n ee) a n d I n vesti gat or’s staff will be e x pecte d t o c o o perat e wit h t he S p o ns or’s St u d y M o nit or, t o be a vaila ble d uri n g a p orti o n of t he m o nit ori n g visit t o a ns wer q uesti o ns, a n d t o pr o vi de a n y missi n g i nf or mati o n. 
Pr ot oc ol A me n d me nt [ADDRESS_664028] y rele va nt material f or t he I n vesti gat or ( or desi g nee) t o s u b mit t o t he I R B f or t he pr ot oc ol’s re vie w a n d a p pr o val. Verific ati o n of t he I R B u n c o n diti o n al a p pr o val of t h e pr ot oc ol a n d t he writte n I C F state me nt will be tra ns mitte d t o t he I n v esti gat or ( or desi g n ee). 
T he I R B will be i nf or me d b y t he I n vesti gat or  ( or desi g nee) of s u bs e q ue nt pr ot oc ol a me n d me nts 
a n d of seri o us a n d u n e x pecte d A Es. A p pr o val f o r pr ot oc ol a me n d me nts will be tra ns mitte d i n writi n g t o t he I n v esti gat or ( or desi g nee). If re q u est e d, t he I n vesti gat or ( or d esi g nee) will per mit 
a u dits b y t he I R B a n d re g ulat or y i ns pe cti o ns b y pr o vi di n g direct access t o s o urce 
data/ d oc u me nts. 
T he I n vesti gat or ( or desi g nee) will pr o vi de t he I R B wit h pr o gress re p orts at a p pr o priate i nter v als 
( n ot t o e xcee d 1 year) a n d a St u d y Pr o gress Re p ort f oll o wi n g t he c o m pleti o n, ter mi nati o n, or disc o nti n uati o n of t he I n vesti gat or ’s ( or d esi g n ee’s) partici pati o n i n t he st u d y. 
8. [ADDRESS_664029] u d y will be o btai ne d fr o m all s u bjects b ef ore 
pr ot oc ol-s pecifi c pr oce d ures are carrie d o ut. T h e I C F will be a p pr o ve d (al o n g wit h t he pr ot oc ol) 
b y t he I R B a n d will be acce pta ble t o t he S p o ns or. 
T he I n vesti gat or ( or desi g nee) will e x plai n t he nat ure of t he st u d y a n d t he acti o n of t he test 
pr o d uct. T he s u bjects will be i nf or me d t hat partici p ati o n is v ol u ntar y a n d t h at t he y ca n wit h dr a w fr o m t he st u d y at a n y ti me. I n acc or da nce wit h [ADDRESS_664030]’s rec or ds.  
8. [ADDRESS_664031]’s e C R F. T o mai ntai n c o nfi de ntiali t y, t he s u bjects will be i de ntifie d o nl y b y n u m bers. 
T he c o m plete d e C R Fs will be tra nsferre d t o t he S p o ns or ( or desi g nee). C o pi [INVESTIGATOR_102182] h e C R F will 
be retai ne d b y t h e I n vesti gat or ( or desi g n ee). All s o urce d oc u m e nts, rec or ds, a n d re p orts will be retai ne d b y t he C R U i n a cc or da n ce wit h 2 1 C F R 3 1 2. 6 2(c). 
Pr ot oc ol A me n d me nt [ADDRESS_664032] 2 0 1 8 Pa ge 5 1 of 6 0 All pri mar y d ata, or c o pi[INVESTIGATOR_014] t here of (e g, la b orat or y rec or ds, e C R Fs, data s h eets, c orres p o n d e nce, 
p h ot o gra p hs, a n d c o m p ut er rec or ds), w hic h are a re s ult of t he ori gi n al o bser vati o ns a n d acti vities of t he st u d y a n d are necessar y f or t he rec o nstr ucti o n a n d e val uati o n of a n y st u d y re p ort, will be retai ne d i n t he C R U arc hi ves. 
8. 8  Refere nce t o Decl ar ati o n of Helsi n ki/ B asic Pri nci ples 
T he st u d y pr oce d ures o utli ne d i n t his pr ot oc ol will be c o n d ucte d i n acc or da nce wit h t he U S C F R 
g o ver ni n g Pr otecti o n of H u ma n S u bjects ( 2 1 C F R 5 0), Fi na ncial Discl os ure b y Cli nical I n v esti gat ors ( 2 1 C F R 5 4), I R Bs ( 2 1 C F R 5 6), I n v esti gati o n al N e w Dr u g A p plicati o n ( 2 1 C F R 3 1 2), A p plicati o ns f or F D A A p pr o val t o Mar ket a Ne w Dr u g ( 2 1 C F R 3 1 4), a n d 
Ra di oacti ve Dr u gs f or Certai n Researc h Us es  ( 2 1 C F R 3 6 1. 1), as a p pr o priate. As s uc h, t hese 
secti o ns of U S Title [ADDRESS_664033] u d y as d escri be d h erei n: 
 
Date P P D
Pr ot oc ol A me n d me nt [ADDRESS_664034] 2 0 1 8 Pa ge 5 4 of 6 0 R E F E R E N C E S 
1. L O X O- 2 9 2 –  I n v esti gat or’s Br oc h ure. ( Versi o n 3.0, 0 5 A pril 2 0 1 8).
Pr ot oc ol A me n d me nt [ADDRESS_664035] 2 0 1 8 Pa ge 5 5 of 6 0 
 A P P E N DI X A - C LI NI C A L L A B O R A T O R Y E V A L U A TI O N S 
Cli nic al C he mistr y P a nel ( F aste d): He m at ol o g y: Uri n al ysis: 
Ala ni ne a mi n otra nsferase He mat ocrit Bilir u bi n 
Al b u mi n He m o gl o bi n C ol or a n d a p peara nce 
Al kali ne p h os p hatase Mea n c or p usc ular he m o gl o bi n Gl uc ose 
As partate a mi n otra nsferase 
Bl o o d urea nitr o ge n Mea n c or p usc ular he m o gl o bi n 
c o nce ntrati o n Ket o nes Le u k oc yte esterase 
Calci u m Mea n c or p usc ular v ol u me Nitrite 
C hl ori de Platelet c o u nt Occ ult bl o o d 
C h olester ol Re d bl o o d cell ( R B C) c o u nt p H a n d s pecific gra vit y 
Creati ni ne R B C distri b uti o n wi dt h Pr otei n 
Gl uc ose W hite bl o o d cell ( W B C) c o u nt Ur o bili n o ge n 
Ir o n  P h os p h or us  
P otassi u m  
S o di u m  T h yr oi d -sti m ulati n g h or m o ne (at 
Scree ni n g o nl y) 
T otal bilir u bi n  T otal pr otei n W B C differe ntial (a bs ol ute a n d 
perce nt ): 
B as o p hils E osi n o p hils L y m p h oc ytes M o n oc ytes Ne utr o p hils Micr osc o pic e xa m i ncl u di n g 
bacteria, casts, cr ystals, e pit helial cells, R B Cs, a n d W B Cs (if pr otei n, le u k oc yte esterase, nitrite, or bl o o d is p ositi ve) 
Tri gl yceri des   
Uric aci d A m ylase  
Li pase   
   
   
Dr u g Scree n: Ser ol o g y:  
I ncl u di n g b ut n ot li mite d t o t he 
f oll o wi n g: He p atitis B s urface a nti ge n He p atitis B c ore a nti b o d y  
He p atitis C vir us a nti b o d y  
Alc o h ol (et ha n ol, Da y - 1 o nl y, b y breat hal yzer ) 
A m p heta mi nes/ met ha m p heta mi nes H u ma n i m m u n o deficie nc y vir us 
a nti b o d y  
B ar bit urates 
B e nz o diaze pi [INVESTIGATOR_512905] n na bi n oi ds   
C ocai ne ( meta b olite) 
C oti ni ne ( b y uri nal ysis)   
Met ha d o ne   
O pi[INVESTIGATOR_858]   
P he nc ycli di ne   
Pr ot oc ol A me n d me nt [ADDRESS_664036] 2 0 1 8 Pa ge 5 6 of 6 0 A P P E N DI X B - B L O O D S A M P LI N G S U M M A R Y 
P art 1 
P ur p ose Ma xi m u m Bl o o d 
V ol u me per Sa m ple 
( m L) Ma xi m u m N u m ber of 
Bl o o d Sa m ples  Ma xi m u m T otal 
V ol u me ( m L) 
Ser ol o g y 4 1 4 
He mat ol o g y 4 4 1 6 
Cli nical C he mistr y 4 4 1 6 
L O X O- 2 9 2 a n d T otal 
Ra di oacti vit y Sa m pli n g 6 2 5a1 5 0
Meta b olite Sa m pli n g 1 0 1 9a 1 9 0 
A p pr o xi m ate T ot al 
Bl o o d V ol u me 3 7 6
P art 2 
Ser ol o g y 4 1 4 
He mat ol o g y 4 4 1 6 
Cli nical C he mistr y 4 4 1 6 
L O X O- 2 9 2, [1 4C]- L O X O- [ADDRESS_664037] es c ollecte d i n P art 1 f or L O X O- 2 9 2/t otal ra di oacti vit y a nal ysis a n d f or 
meta b olite pr ofili n g/c haracteri zati o n  is base d o n s u bj ect c o nfi ne me nt u ntil Da y [ADDRESS_664038] 2 0 1 8 Pa ge 5 7 of 6 0 
 A P P E N DI X C - A D V E R S E E V E N T S 
1  A D V E R S E E V E N T S 
1. 1  Defi niti o n of A d verse E ve nts 
A n a d vers e e ve nt ( A E; or a d verse e x perie nce) is defi ne d as a n y u nt o war d me dical occ urre n ce 
e x perie nce d b y a p atie nt or healt h y s u bject, w h et her or n ot c o nsi dere d dr u g relate d b y t he I n v esti gat or ( or desi g n ee). A treat me nt- e mer ge nt A E is a n A E t hat is re p orte d after a d ose of st u d y dr u g. 
T he f oll o wi n g are all A Es: 
 U nfa v ora ble c h a n ges i n ge n eral c o n diti o n; 
 S u bjecti ve or o bjecti ve si g ns/s y m pt o ms;  C o nc o mita nt diseases or acci de nts; 
 Cli nicall y rele v a nt a d verse c ha n ges i n la b orat or y para meters o bser ve d i n a s u bject d uri n g 
a cli nical st u d y. 
A d verse e ve nts c o m prise all dist ur ba nces of ge ne ral healt h stat us, s u bjecti ve a n d o bjecti ve 
disease s y m pt o ms (i ncl u di n g la b orat or y a b n or m alities), a n d acci de nts o bser ve d i n t he c o nte xt of a cli nical trial, irres pecti v e of a p ossi ble ca usal rel ati o ns hi p wit h t he a d mi nistrati o n of t he trial s u bsta nce. E ve nts oc c urri n g i n t he fra me w or k of a cli nical trial d uri n g dr u g-free a n d p ost-treat me nt peri o ds, u n der place b o, or i n a re fere nce gr o u p recei vi n g dr u g or n o n dr u g t hera p y 
are als o t o be d esi g n ate d as A Es. All A Es, c o m plai nts, or s y m pt o ms t hat occ ur fr o m t he ti me 
i nf or me d c o nse nt is si g n e d u ntil t he Safet y F oll o w- u p Call are t o be rec or de d o n t he a p pr o priate electr o nic Cas e Re p ort F or m (e C R F ) (e ve nts t hat occ ur pri or t o c o nse nt are c o nsi der e d me di cal hist or y). D o c u me ntati o n m ust be s u p p orte d b y a n e ntr y i n t he p atie nt’s s o ur ce me dical rec or ds. La b orat or y test a b n or malities c o nsi dere d b y t he I n vesti gat or t o b e cli nicall y rele va nt s h o ul d be re p orte d i n t he e C R F as a n A E. Eac h A E is t o be e val u ate d f or d urati o n, se v erit y, a n d ca us al relati o ns hi p wit h t he i n vesti gati o nal pr o d uct or ot h er fact ors. 
1. 2  C ate g oriz ati o n of A d verse E ve nts 
T he se verit y of A Es will be cate g orize d ba se d o n t he Nati o nal Ca ncer I nstit ute C o m m o n 
Ter mi n ol o g y Criteri a f or A d verse E v e nts ( C T C A E) Versi o n 5. 0 as f oll o ws: 
 Gr a de 1 Mil d : As y m pt o matic or mil d s y m pt o ms; cli nical or dia g n ostic o bser vati o ns 
o nl y; i nter ve nti o n n ot i n dicate d 
 Gr a de 2 M o der ate : Mi ni mal, l ocal or n o ni n vasi ve i nter ve nti o n i n dicate d; li miti n g a ge-
a p pr o priate i nstr u me nt al Acti vit ies of Dail y Li vi n g ( A D L) *  
Pr ot oc ol A me n d me nt [ADDRESS_664039] 2 0 1 8 Pa ge 5 8 of 6 0 
  Gr a de 3 Se v ere o r me di c all y si g nific a nt b ut n ot i m me di atel y lif e t hre ate ni n g : 
H os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of h os pi[INVESTIGATOR_27967] o n i n dicate d; disa bli n g; li miti n g self- care 
A D L * *  
 Gr a de 4 Lif e-t hre ate ni n g c o nse q ue nces : Ur ge nt i nter ve nti o n i n dicate d 
 Gr a de 5 D e at h rel ate d t o A E  
N ote: N ot all gra d es are a p pr o priate f or all A Es. T heref ore, s o me A Es are liste d wit hi n t he C T C A E wit h fe wer t ha n 
5 o pti o ns f or gra d e selecti o n. Gra d e 5 ( deat h) is n ot a p pr o priate f or s o me A Es a n d t heref ore is n ot a n o pti o n.  * I nstr u me ntal A D L refer t o pre pari n g meals, s h o p pi n g f o r gr oceries or cl ot hes, usi n g t he t ele p h o ne, ma na gi n g m o ne y, etc.  * * S elf-care A D L refer t o bat hi n g, dressi n g a n d u n dressi n g, fee di n g self, usi n g t he t oilet, ta ki n g me dic ati o ns, a n d n ot be dri d de n. 
T he I n vesti gat or ( or desi g nee) will ma ke a dete r mi nati o n of t he relati o ns hi p of t he A E t o t he 
st u d y dr u g usi n g a 2- cate g or y s yste m acc or di n g t o t he f oll o wi n g g ui deli nes: 
 N O T R E L A T E D  = T he ti me c o urse bet w ee n t he a dmi nistrati o n of i n vesti gati o nal pr o d uct a n d t he occ urre n ce or w orse ni n g of t he A E r ules o ut a ca us al relati o ns hi p a n d a n ot her ca use (e g, c o nc o mita nt dr u gs, t h era pi[INVESTIGATOR_014], c o m plicati o ns, c o m or bi dities) is 
s us pecte d; 
 R E L A T E D  = T he ti me c o urse bet wee n a d mi nistrati o n of i n vesti gati o nal pr o d uct a n d t he 
occ urre nce or w ors e ni n g of t he A E is c o nsiste nt wit h a ca usal r elati o ns hi p a n d n o ot her ca use (e g, c o n c o mita nt dr u gs, t hera pi[INVESTIGATOR_014], c o m p licati o ns, c o m or bi dities) ca n be i de ntifie d. 
A n A E is ass ociate d wit h t he use of t he dr u g if t h ere is a reas o na ble p ossi bilit y t h at t he e x perie nce ma y h a ve bee n ca use d b y t he dr u g. 
T he acti o n ta ke n wit h t he i n vesti gati o nal pr o d u ct i n res p o nse t o t he A E s h o ul d be pr o vi de d at t he 
ti me t he e ve nt is re p orte d. F or t his st u d y, o pti o ns f or acti o n ta ke n i ncl u d e t he f oll o wi n g: 
 D osi n g st o p pe d :  Me dicati o n a d mi nistrati o n was st o p pe d bef ore or d uri n g d osi n g. 
1. [ADDRESS_664040] u d y dru g a d mi nistrati o n s h o ul d be re p orte d b y t he I n v esti gat or ( or desi g n ee) via e Fa x t o t he S p o ns or’s C o ntact f or Seri o us A d verse E ve nt 
Re p orti n g liste d i n t he St u d y I d e ntificati o n secti o n wit hi n 2 4 h o urs of bei n g n otifie d. T he 
S p o ns or’s C o ntact f or Seri o us A d verse E v e nt Re p orti n g will t he n f or war d t he Pre g na nc y F or m 
t o t he I n v esti gat or ( or d esi g nee) f or c o m pleti o n. 
e F a x: + 1 ( 2 0 3) 6 4 3- 2 0 1 3 
T he part ner s h o ul d be f oll o we d b y t h e I n vesti gat or ( or desi g nee) u ntil c o m pleti o n of t he 
pre g na nc y. If t he pre g na nc y e n ds f or a n y reas o n bef ore t h e a ntici pate d d ate, t he I n vesti gat or ( or 
Pr ot oc ol A me n d me nt [ADDRESS_664041] 2 0 1 8 Pa ge 5 9 of 6 0 
 desi g nee) s h o ul d n otif y t he S p o ns or’s C o ntact f or Seri o us A d verse E v e nt Re p orti n g. At t he 
c o m pleti o n of t he pre g n a nc y, t h e I n vesti gat or ( or desi g nee) will d oc u me nt t he o utc o me of t he pre g na nc y. If t he o utc o m e of t he pre g na nc y m eets t he criteria f or i m me diat e classificati o n as a seri o us A E ( S A E) (i e, p ost part u m c o m plicati o n, s p o nta ne o us a b orti o n, still birt h, ne o natal deat h, or c o n ge nital a n o mal y), t he I n vesti gat or ( or desi g nee) s h o ul d f oll o w t he pr oce d ures f or re p orti n g a n S A E. 
Male s u bjects will be i nstr ucte d t o n otif y t he I n vesti gat or ( or desi g nee) i m me diatel y if t he y 
disc o ver t heir se x ual part ner is pre g na nt. I n t his i nsta nce, t he part ner m ust pr o vi de writte n c o nse nt bef ore pre g na nc y i nf or m ati o n ca n be c o llecte d. W he n a site bec o mes a ware t hat t he fe male part ner of a male s u bject is pre g na nt, t he y are t o c o ntact t he C o va nce Me dical M o nit or 
i m me diatel y ( wit hi n 2 4 h o urs of t he site staff bec o mi n g a w are of t he e v e nt) i n a d diti o n t o 
n otif yi n g t he S p o ns or’s C o ntact f or Seri o us A d verse E ve nt Re p orti n g via e Fa x. 
1. 4  Defi niti o n of Seri o us A d verse E ve nts 
A n S A E ( b y F o o d a n d Dr u g A d mi nistrati o n [ F D A] defi niti o n) is a n y a d verse dr u g e x perie nce 
occ urri n g at a n y d ose t hat res ults i n a n y of t h e f oll o wi n g o utc o mes: 
 Deat h; 
 A life-t hreate ni n g a d vers e dr u g e x perie nce (ie, o n e t hat places t he s u bj ect, i n t he vie w of 
t he I n v esti gat or [ or desi g nee], at i m me diate ris k of deat h; it d oes n ot mea n a n e ve nt t hat, 
ha d it occ urre d i n a m ore se vere f or m, mi g ht h a ve ca use d deat h); 
 I n p atie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_27967] o n; 
 A persiste nt or si g nifica nt disa bilit y/i nca p acit y; 
 A c o n ge nital a n o mal y/ birt h defect; 
 A n i m p orta nt me dical e v e nt t hat ma y re q uir e me dical or s ur gical i nter ve nti o n t o pre ve nt 
o ne of t he a b o v e o utc o m es. 
I m p ort a nt me dical e v e nts t hat ma y n ot r es ult i n deat h, be life t hreate ni n g, or re q uire 
h os pi[INVESTIGATOR_1314] o n ma y be c o nsi dere d S A Es w he n, b ase d o n a p pr o priate me di cal j u d g m e nt, t he y ma y je o p ar dize t he patie nt or s u bject a n d ma y re q uire me dical or s ur gical i nter ve nti o n t o pre ve nt o ne of t he o utc o mes liste d i n t his defi niti o n.  
1. [ADDRESS_664042] u g e x perie nce, t h e s pecificit y or 
se verit y of w hic h is n ot c o nsiste nt wit h t he c urre nt I n v esti gat or’s Br oc h ure (I B) or, if a n I B is n ot re q uire d or a vaila ble, t h e s pecificit y or se v erit y of w hic h is n ot c o nsiste nt wit h t he ris k i nf or mati o n descri be d i n t he ge neral i n vesti gati o nal pla n or else w h ere i n t h e c urre nt a p plicati o n, as a me n de d. 
Pr ot oc ol A me n d me nt [ADDRESS_664043] u g A d mi nistrati o n-re p ort a ble A Es will be re p orte d b y t he Cli nical Researc h U nit t o t he S p o ns or, t he C o va nce M e dic al M o nit or, a n d t he res p o nsi ble I nstit uti o nal Re vie w B o ar d (I R B). 
Wit hi n [ADDRESS_664044] rec o g niz e d or re p orte d, 
a n d wit hi n 2 4 h o urs of a n y S A E –  eit her e x pe dite d or n o ne x pe dite d –  bei n g first r ec o g niz e d or re p orte d, t he S p o ns or’s C o ntact f or Seri o us A d v erse E ve nt Re p orti n g will be n otifie d b y t h e 
I n v esti gat or ( or desi g n ee) i n writi n g (e g, facsi mile) usi n g t he f oll o wi n g e Fa x n u m ber: 
e F a x: + 1 ( 2 0 3) [ADDRESS_664045] be re p orte d. T o re p ort t he S A E a n d/ or p ote ntiall y F D A-re p orta ble A E, t he c o m plete d S A E Re p ort F or m will be se nt b y e Fa x  wit hi n [ADDRESS_664046] u d y Ma n ual.  
T he I n vesti gat or ( or desi g nee) is n ot o bli gate d t o acti vel y see k i nf or mati o n re gar di n g t he 
occ urre nce of ne w S A Es be gi n ni n g after t he Safet y  F oll o w- u p Call. H o we v er, if t he I n v esti gat or ( or desi g nee) lear ns of s u c h a n S A E, a n d t hat e v e nt is dee m e d rele v a nt t o t he use of st u d y dr u g, he/s he s h o ul d pr o m ptl y d oc u me nt a n d re p ort t he e ve nt. T he I n vesti gat or ( or desi g nee) will be 
re q ueste d t o s u p pl y detaile d i nf or mati o n as well as f oll o w- u p re gar di n g t he S A E.  
T he I R B will be n otifie d of a n y F D A-re p orta ble A E wit hi n t he ti mefra me re q uire d b y t he I R B. 
T he I R B Seri o us a n d U n e x pecte d A d vers e E x perie nce S u b missi o n F or m will be c o m plete d a n d s u b mitte d wit h t he c o p y of t he writte n c o nfir mati o n or s u m mar y of t he A E.   